Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
04/2011 | Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/28/2011 > patent applications in patent subcategories. category listing, related patent applications

20110098211 - Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for... Agent: Pieris Ag

20110098212 - Cytokine: A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.... Agent:

20110098213 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk A/s

20110098214 - Lps or lipid a binding agent and novel peptide: A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS... Agent: Peptide Door Co., Ltd.

20110098215 - Peptides and methods of use as therapeutics and screening agents: Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that... Agent:

20110098216 - Therapeutic uses of colostrinin: There is provided the use of Colostrinin for the treatment of obesity.... Agent: Regen Therapeutics PLC

20110098217 - Compounds exhibiting glucagon antagonist and glp-1 agonist activity: Glucagon analogs are disclosed that exhibit both glucagon antagonist and GLP-1 agonist activity. In one embodiment, the glucagon antagonist/GLP-1 agonist comprises a modified amino acid sequence of native glucagon, in which the first one to five N-terminal amino acids of native glucagon is deleted and in which the alpha helix... Agent: Indiana University Research And Technology Corporation

20110098218 - Modulators of stat3 signalling: The invention relates to methods for identifying compounds which modulate the interaction between STAT3 an SP1. A peptide is provided which is able to bind STAT3 and interfere with the interaction of STAT3 and SP1. The invention provides methods for identifying compounds which are capable of binding to the peptide... Agent: Agency For Science, Technology And Research

20110098219 - System for curing hepatic cancer with leptin: The present invention cures hepatic cancer by MPA with the help of leptin. A therapeutic drug of MPA combined with leptin is applied to a liver cancer patient. Or, MPA can be directly applied to a patient having a high leptin expression. Or, if a patient has a low leptin... Agent: Kaohsiung Medical University

20110098220 - Methods and kits for preventing hypoglycemia: The present invention provides improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated... Agent: Cebix Ab

20110098221 - Inhibitors of akt activity: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent:

20110098222 - Glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16,... Agent: Zealand Pharma A/s

20110098223 - Use of the pat nanopeptide in the treatment of autoimmune diseases: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.... Agent:

20110098224 - Protein kinase c peptide modulators of angiogenesis: The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner.... Agent:

20110098225 - Novel peptides derived from ncam (fgls): The present invention relates to novel compounds comprising at most 13 contiguous amino acid residues derived from the fibronectin type 3,I1 module of neural cell adhesion molecule (NCAM), or a variant or fragment thereof, capable of interacting with an FGFR and thereby the compounds are capable of inducing differentiation, modulating... Agent: Enkam Pharmaceuticals A/s

20110098226 - Small molecular weight tnf receptor multimeric molecule: The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the... Agent: The Kennedy Institute Of Rheumatology

20110098227 - Soluble notch-based substrates for gamma secretase and methods and compositions for using same: The present invention is directed to novel soluble substrates for γ-secretase. More particularly, the invention provides a soluble fusion polypeptide with a Notch segment containing the γ-secretase-dependent cleavage sites (γ and ε) fused to a NusA protein. Methods and compositions for making and using such a fusion protein are disclosed.... Agent:

20110098228 - Synthetic analogues of neural regeneration peptides: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing β-turns, acetylation of terminal glycine residues or by... Agent: Neuren Pharmaceuticals Limited

20110098229 - Compositions and methods for treating dermatological conditions: Provided herein are methods of improving one or more symptoms of a dermatological condition in a patient. The methods comprise topically administering a topical composition to the patient comprising a branched chain amino acid, and an enzyme activator. Also provided are kits comprising the topical composition and optionally a topical... Agent:

20110098230 - Cosmetic use of annexin ii-type proteins for treating dryness of the skin: o

20110098231 - Skin cosmetic: The present invention provides a skin cosmetic having superior sensation during use and stability and also maximally manifesting the various effects of ingredient (A), which is β-alanyl-L-histidine and/or its salt, by preparing a mildly acidic skin cosmetic by characteristically using ingredient (A) and ingredient (B), which is a thickener composed... Agent: Shiseido Company, Ltd.

20110098232 - Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis: Available evidence indicates that tumor cells exhibit consistent abnormalities in Calcium influx and intracellular storage of sequestered Calcium when compared to normal cells. The present invention provides clinical methods by which such differences are exploited to induce Apoptosis selectively in tumor cells while sparing normal cells. These methods are based... Agent:

20110098233 - Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same: WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL. The present invention also relates to a peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which... Agent:

20110098235 - Antineoplastic peptides: 1

20110098234 - Breast cancer proteins: The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member... Agent:

20110098236 - Diamide inhibitors of cytochrome p450: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect... Agent: Sequoia Pharmaceuticals, Inc.

20110098237 - Methods for inhibiting drug degradation: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect... Agent: Sequoia Pharmaceuticals, Inc.

20110098238 - Elucidating ligand-binding information based on protein templates: A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that... Agent: Georgia Tech Research Corporation

20110098239 - Novel diaryl hepatonoid-based compounds and use thereof: The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds... Agent:

20110098240 - Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor: The invention relates to a pharmaceutical composition according to claim 1 comprising a SGLT2 inhibitor in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.... Agent: Boehringer Ingelheim International Gmbh

20110098242 - Methods and compositions for diagnosing and treating cervical intraepithelial neoplasia and cervical cancer: Disclosed herein are methods and compositions for diagnosing and treating diseases associated with a loss of cystatin E/M expression including cervical intraepithelial neoplasia and cervical cancer. Genetic mutations and exonic deletions which result in a loss of cystatin E/M expression are also disclosed.... Agent:

20110098241 - Rapamycin analogs as anti-cancer agents: Analogs and derivatives of rapamycin are provided, wherein the analogs and derivatives can bind to FK-506 binding protein (FKBP), or inhibit the mTOR function of an FKBP, or both. The analogs and derivatives are rapamycin include the rapamycin skeleton substituted at the 42-hydroxyl group with certain specified chemically feasible groups.... Agent: Poniard Pharmaceuticals, Inc.

20110098343 - Antisense formulation: A room temperature stable and minimal aggregate liquid formulation comprises an oligonucleotide comprising Seq ID No. 1: or comprising a variant oligonucleotide in which no more than 3 non-sequential bases are different from Seq. ID NO. 1 and an aqueous carrier comprising a aggregation-preventing compound selected from the group consisting... Agent: Oncogenex Technologies Inc.

20110098340 - Antisense modulation of bcl2-associated x protein expression: Antisense compounds, compositions and methods are provided for modulating the expression of BCL2-associated X protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding BCL2-associated X protein. Methods of using these compounds for modulation of BCL2-associated X protein expression and for treatment of diseases associated with... Agent: Isis Pharmaceuticals, Inc.

20110098339 - C2orf18 as target gene for cancer therapy and diagnosis: Described herein are objective methods for detecting or diagnosing a predisposition to developing cancer, particularly pancreatic cancer. In one embodiment, the diagnostic method involves the step of determining an expression level of C2orf18 using anti-C2orf18 antibody. The present invention further provides methods of screening for therapeutic agents useful in the... Agent: Oncotherapy Science, Inc.

20110098344 - Drug carrier: s

20110098337 - Inhibitors of rtp801 and their use in disease treatment: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.... Agent: Quark Pharmaceuticals, Inc.

20110098342 - Methods of detecting long range chromosomal interactions: The present invention relates to a method of monitoring epigenetic changes comprising monitoring changes in conditional long range chromosomal interactions at at least one chromosomal locus where the spectrum of long range interaction is associated with a specific physiological condition, the method comprising the steps of: —(i) in vitro crosslinking... Agent: Oxford Biodynamics Limited

20110098338 - Rna interference for the treatment of heart failure: The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart... Agent:

20110098341 - Use of id4 for diagnosis and treatment of cancer: The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed... Agent:

20110098345 - Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before,... Agent:

20110098346 - Nucleic acid molecule and method of targeting gene expression to gliomas: There is presently provided a nucleic acid molecule comprising a glial-specific promoter; a coding sequence for a transgene; and a plurality of miRNA target sites. Each miRNA target site binds an miRNA that is down-regulated in .a glioma cell compared to a normal glial cell, and the glial-specific promoter and... Agent: Agency For Science, Technology And Research

20110098243 - Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification: Aortic valve stenosis (AS) is a chronic process related to a progressive mineralization of the aortic root and valve cusps. We found in human AS valves a high level of expression and enzymatic activity of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP-1), which correlated to the degree of mineralization. In vitro, inhibition of ENPP... Agent:

20110098244 - Process for isolating sialic acid containing oligosaccharides, and the compositions containing sialic acid containing oligosaccharides obtainable thereby: The invention relates to a process for isolating sialic acid containing oligosaccharides and in particular sialyllactose from a milk stream and especially from a whey stream. The process yields a product having a high content of sialyllactose and a low content of phosphorus compounds. This product is highly suitable to... Agent:

20110098245 - Agent for preventing or ameliorating obesity: The present invention provides a method for preventing or ameliorating obesity, for inhibiting accumulation of visceral fat, for inhibiting accumulation of liver lipid, for preventing or ameliorating fatty liver, including using a material for a pharmaceutical product or food, which has inhibitory actions on body weight increase, accumulation of visceral... Agent: Kao Corporation

20110098246 - Method for preventing corticosteroid usage: The present invention relates to the use of nutritional compositions comprising non-digestible oligosaccharides for preventing corticoid administration, particularly to infants.... Agent: N.v. Nutricia

20110098247 - Substituted dihydroquinazolines as platelet adp receptor inhibitors: e

20110098248 - Modulators of toll-like receptors: The present application includes novel modulators of TLRs, compositions containing such compounds, therapeutic methods that include the administration of such compounds.... Agent: Gilead Sciences, Inc.

20110098249 - Compositions and methods of treatment for alleviating premenstrual syndrome symptoms: The present invention discloses pharmaceutical/nutritional compositions for alleviating symptoms associated with premenstrual syndrome (PMS) and methods of treatment for PMS using such pharmaceutical/nutritional composition including: at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total composition, as an effective ingredient, wherein: the phosphatidyl-L-serine has a structural fatty-acid chain... Agent: Lipogen Ltd.

20110098250 - Water-soluble benzoazepine compound and its pharmaceutical composition: wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and... Agent: Otsuka Pharmaceutical Co., Ltd.

20110098251 - Bisphosphonate compounds: Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.... Agent: Warner Chilcott Company, LLC

20110098252 - Treatment of spinal mechanical pain: The invention is directed to a method of treating chronic spinal mechanical pain by intravenous administration to a subject in need of chronic spinal mechanical pain relief of an effective amount of bisphosphonate.... Agent: New York University

20110098253 - Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use: The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases... Agent: Nicox S.a.

20110098254 - Compositions comprising phospholipids: The present invention provides compositions comprising phospholipids and particularly those comprising at least 40% phospholipid and at least 80% phospholipid as a percentage of total fat in the extract, comprising polyunsaturated and saturated phospholipids, in a ratio of saturated phospholipid to monounsaturated to polyunsaturated phospholipid of about 6:3:1 respectively, or... Agent:

20110098255 - Combination of a parp inhibitor and an akt kinase activating compound: The primary subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination in the treatment of pathological conditions related to PARP activation and/or that could benefit from Akt activation. A further subject of the invention is the use of a PARP... Agent:

20110098256 - Method for making and using a topical dermatological solution: A novel method for making and using topical dermatological solution for external use which is effective in treating dermatological disorders. The methods include administering a therapeutically effective amount of a topical dermatological solution comprising pre-mixed agents which can affect a variety of inflammatory conditions of the skin thus treating a... Agent:

20110098257 - Derivatives of 4- or 5-aminosalicylic acid: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon... Agent: Antibe Therapeutics Inc.

20110098258 - Transdermal pharmaceutical compositions comprising active agents: The present invention provides compositions and methods for providing sustained release of an active agent through the skin of a subject, wherein a pharmaceutical percutaneous composition comprises at least one fatty acid ester and a therapeutically effective amount of active agent.... Agent: Besins Healthcare Luxembourg

20110098259 - Pregnane steroids and their use in the treatment of cns disorders: Steroid compounds possessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the... Agent: Umecrine Cognition Ab

20110098260 - Steroid compounds and formulations: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Harbor Biosciences, Inc.

20110098261 - Triterpenoid-based compounds useful as virus inhibitors: The present invention relates to the use of triterpenoid-based compounds of formula (1) for inhibiting viral activity. The triterpenoid-based compounds have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.... Agent:

20110098262 - Corroles for neuroprotection and neurorescue: Transition metal complexes of amphiphilic corroles, optical isomers and pharmaceutically acceptable salts thereof are useful for neuroprotection and neurorescue, particularly for treatment of diabetes and neurodegenerative diseases. The amphiphilic corrole is preferably a 5,10,15-tris-aryl- or 5,10,15-tris-CF3-corrole, and said transition metal complex more preferably has the formula I defined in the... Agent:

20110098263 - Hydroxy-substituted cold(iii) porphyrin complexes as histone deacetylase inhibitors: a

20110098265 - Methods for reducing cravings and impulses associated with addictive and compulsive behaviors: This document provides methods and materials related to managing weight, supporting appetite control, and controlling cravings associated with smoking reduction or cessation regimens and/or nicotine reduction or cessation regimens. For example, compositions comprising an agent to support acetylcholine and an agent to support one or more biogenic amines, and methods... Agent: Neuroscience, Inc.

20110098264 - Pharmaceutical composition containing cyclometalated n-heterocyclic carbene complexes for cancer treatment: The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of... Agent: The University Of Hong Kong

20110098266 - Method of administering an injectable antibiotic to an animal: A method of administering an antibiotic to an animal in need thereof, including the step of injecting the antibiotic subcutaneously at the junction of a pinna with the cranium of the animal, is disclosed.... Agent: Pharmacia & Upjohn Company LLC

20110098270 - Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase: Thiazolopyrimidine compounds of formula I, where W represents a thiazole ring, selectively inhibit the p110 delta subtype of PI3 Kinase (PI3K), and are useful for treating diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection,... Agent:

20110098271 - Chromenone derivatives: or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the... Agent: Astrazeneca Ab

20110098272 - Novel compounds as casein kinase inhibitors:

20110098268 - Spirocyclic compounds: The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention... Agent: Merck & Co., Inc

20110098269 - Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands: e

20110098267 - Topical formulations for the treatment of psoriasis: The invention relates to a topical composition and a method for treating psoriasis. The topical composition comprises one or more compound that inhibits the production of IL-12 and IL-23.... Agent: Synta Pharmaceuticals Corporation

20110098273 - Oligomer-calcium channel blocker conjugates: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the... Agent: Nektar Therapeutics

20110098274 - Polycyclic heteroaryl substituted triazoles useful as axl inhibitors: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110098275 - 5-alkynyl-pyridines: l

20110098276 - Oxycarbamoyl compounds and the use thereof:

20110098277 - Fab i inhibitors: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.... Agent:

20110098278 - Galantamine amino acid and peptide prodrugs and uses thereof: Prodrugs of galantamine or its 3-hydroxy metabolite with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and methods for treating a memory or cognition disorder with the galantamine prodrugs are provided herein. Prodrugs having side chains of valine, phenylalanine, tyrosine or para amino benzoic acid and mono-, di-... Agent: Shire LLC

20110098280 - 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders: o

20110098279 - Use of triazolopyrimidine derivatives as microbicides:

20110098281 - Benzenesulfonyl compounds and the use thereof: The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1, R2, Z and m are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat a disorder... Agent: Purdue Pharma L.p.

20110098283 - 3-cinnolinecarboxamide derivatives and their use for treating cancer: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and... Agent: Astrazeneca Ab

20110098282 - New compounds: Novel compounds of which the following is exemplary:... Agent: Boehringer Ingelheim International Gmbh

20110098284 - Methods and compositions for treating pain: The present invention provides a method of treating or preventing pain, inflammation or fever comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more selected NSAIDs, in racemic, enantiomeric excess, or enantiomeric form, in combination with ethylenediamine and/or piperazine.... Agent:

20110098285 - Bicyclic-substituted amines as histamine-3 receptor ligands: e

20110098286 - (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides a process for the preparation of the compounds of formula I. The... Agent: H. Lundbeck A/s

20110098287 - Novel heteroaromatic amides and thioamides as pesticides: The present application relates to novel amides and thioamides, to processes for preparation thereof and to use thereof for controlling animal pests, in particular arthropods and especially insects.... Agent: Bayer Cropscience Ag

20110098288 - Sulfonamides as zap-70 inhibitors: wherein R1 to R9 and R4a have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the... Agent:

20110098289 - Method for treating obesity: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition... Agent:

20110098290 - Pharmaceutical compounds: e

20110098291 - Antagonist of smoothened: Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary diseases and disorders.... Agent: Alla Chem Inc.

20110098293 - Inhibitors of protein tyrosine kinase activity: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions... Agent:

20110098292 - New compounds useful for treating cns disorders: The present invention provides new compounds of formula (I) as well as a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.... Agent: Astrazeneca Ab

20110098295 - Methods of treating anxiety, itching and psychiatric disorders: A method of treating an undesirable AC8-related condition in a mammal is provided comprising the step of inhibiting AC8 in the mammal... Agent:

20110098294 - Purine analogs: The present invention provides a new patentable class of purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals.... Agent:

20110098297 - Fused ring compounds and use thereof: The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in... Agent: Takeda Pharmaceutical Company Limited

20110098296 - Thiazole and oxazole kinase inhibitors: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent:

20110098300 - Compounds comprising a cyclobutoxy group: The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals, useful for the treatment and prevention of diseases or pathological conditions of the central nervous system including mild-cognitive impairments, Alzheimer's disease, learning and;... Agent: Ucb Pharma, S.a.

20110098298 - New pyridin-3-amine derivatives: e

20110098299 - Spirolactam derivatives and uses of same:

20110098301 - Pyrimidine derivatives for treatment of hyperproliferative disorders:

20110098302 - Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other... Agent: Amira Pharmaceuticals, Inc.

20110098303 - Method of promoting nail growth using thyromimetic compounds: The present invention provides methods and compositions for increasing the rate of nail growth in mammals, especially humans, using thyromimetic compounds.... Agent:

20110098305 - Arylsulfonamide compounds, compositions and methods of use: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent:

20110098304 - Small molecule inhibitors of parp activity: Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such componds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.... Agent:

20110098307 - Crystalline of eszopiclone, its composition, preparation and uses thereof: The present invention discloses a crystalline form of S-zopiclone having a powder X-Ray diffraction spectrum excited by Cu-Ka radiation with characteristic peaks expressed in terms of 28 at about 11.08°, about 12.38°, about 15.86°, about 17.88°, about 19.98° and about 20.58°; a DSC thermogram with a peak at about 207.7°... Agent: Tianjin Tasly Group Co., Ltd.

20110098306 - Uses of tetrahydrobiopterin, sepiapterin and derivatives thereof: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel... Agent:

20110098308 - Azaindazole compounds and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Chemocentryx, Inc.

20110098309 - Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide... Agent: Acumen Pharmaceuticals, Inc.

20110098311 - Compositions for treatment of cystic fibrosis and other chronic diseases: The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions... Agent: Vertex Pharmaceuticals Incorported

20110098310 - Novel compounds, use and preparation thereof: The present invention relates to compounds of the general formula (I) wherein R1, R2 and R3 are as defined herein, which can act as inhibitors of protein kinases, specially the Fms-like tyrosine kinase 3 (FLT3). The invention also relates to the use of the compounds in therapy, pharmaceutical compositions comprising... Agent:

20110098312 - Methods for preventing the development of retinopathy by the oral administration of nnr ligands: Method and compositions for delaying the onset or progression of retinopathy, including administering at least one neuronal nicotinic ligand are disclosed.... Agent: Targacept ,inc

20110098313 - Positive allosteric modulators (pam): R1, R2, X, L, R3, R4, R4′, cyc, and n are as defined in the specification and claims and to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM)... Agent:

20110098315 - Pharmaceutical compositions of rosuvastatin calcium: This invention is related to pharmaceutical compositions of rosuvastatin or pharmaceutically acceptable salts thereof especially calcium salt with sodium carbonate anhydrous which has effects on dissoltion profiles in 0.1 N HCI medium provided that using of sodium carbonate anhydrous should be presence in the range of from about 0.5% to... Agent:

20110098314 - Statins for the treatment of ocular hypertension and glaucoma: The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via... Agent: Alcon, Inc.

20110098316 - Chromane derivatives as trpv3 modulators: The present invention provides chromane derivatives as transient receptor potential vanilloid (TRPV) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof,... Agent: Glenmark Pharmaceuticals S.a.

20110098317 - Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the... Agent: Research Foundation Of The City University Of New York

20110098318 - Farnesyl protein transferase inhibitors for treating breast cancer: The present invention relates to the use of farnesyl protein transferase inhibitors for preparing pharmaceutical compositions for treating advanced breast cancer.... Agent:

20110098319 - Fatty acid derivatives for oral administration endowed with high palatability: The invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, useful for all the known clinical applications of the latter, which show physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterize butyrate. The new compounds are... Agent:

20110098320 - Lactam inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (I*), (Ia), (Ib), (Ic), (Id), (Ie), (If), (If*), (Ig), (Ih), (Ij), (Ik), (ll1-3), (Im1-3), (In1-3), (lo1-2), (Ip1-9), (Iq1-9), (Ir1-9) and (Is1-3) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with... Agent: Vitae Pharmaceuticals, Inc.

20110098321 - Salts of methyl 2-((r)-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3-((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate: are disclosed. In particular, single crystalline mucic acid salts of the compound represented by structural formula (I) are characterized by a variety of properties and physical measurements. Methods of producing the mucic acid salts, using the salts to antagonize one or more aspartic proteases, and methods of treating a number... Agent:

20110098322 - Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase: The present invention provides compounds that can inhibit the activity of soluble epoxide hydrolases. In particular, the present invention provides compounds of Formula I.... Agent: The Regents Of The University Of California

20110098323 - Inhibitors of bacterial biofilm formation: Organic compounds are described for use in inhibiting or preventing formation of bacterial biofilms.... Agent: Microbiotix, Inc.

20110098324 - Prolyl hydroxylase inhibitors: g

20110098325 - Pyridine benzamides and pyrazine benzamides used as pkd inhibitors: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions... Agent: Cancer Research Technology Limited

20110098326 - 2-fluorothiazole derivatives useful as imaging agents; methods of synthesis, and methods of use: Novel 18F-labeled thiazole derivatives useful for imaging of metabotropic glutamate subtype 5 receptors (mGluR5) in living mammalian brain are disclosed herein. Also disclosed herein is a synthetic method for making the claimed thiazole derivatives under thermal heating or microwave conditions for aryl thioethers that provides the compounds in high yield.... Agent:

20110098327 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method... Agent: Bristol-myers Squibb Company

20110098328 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110098329 - Catalyzed carbonylation in the synthesis of angiotensin ii antagonists: One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic... Agent: Lek Pharmaceuticals D.d.

20110098330 - Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors: A compound having selective modulating activity at the alpha 2B and or alpha 2C adrenergic receptor subtypes is represented by the general Formula (1): wherein R1-R6 is independently selected from the group consisting of H, C1-6 alkyl, halogen, CH2OH, CH2N(R7)2)CH2CN, C(O)R8, CF3, and aryl; wherein R7 is H or C1-6... Agent:

20110098331 - Haloalkylsubstituted aryloxyalkylimidazolines for use as pesticides: The present invention relates to novel imidazoline derivatives and their use as insecticidal, acaricidal, mollus and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and... Agent: Syngenta Crop Protection, Inc.

20110098332 - Insecticides for increasing the crop yield: The present invention relates to the use of at least one insecticide selected from GABA antagonists for increasing the crop yield of at least one plant variety and to a method for increasing the crop yield of at least one plant variety by treating the propagules from which it is... Agent: Basf Se

20110098333 - Methods for treating or preventing brain infections: The invention is directed to methods of treating organ specific infections in a host organism by administering compounds that target host receptors and/or host cellular signaling molecules to prevent a pathogen from infecting the organ. For example, the administration of a compound to prevent a pathogen from crossing the blood-brain... Agent: The Johns Hopkins University

20110098335 - Novel compounds: e

20110098334 - Novel crystalline form of calcium zofenopril: The present invention relates to a novel anhydrous crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt or hemi-calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium, its use in pharmaceutical compositions and... Agent: Generics [uk] Limited

20110098336 - Pyrrolidin-2-one derivatives as androgen receptor modulator: A compound represented by the formula (I) according to claim 1 or a salt thereof has a superior androgen receptor modulating action.... Agent: Takeda Pharmaceutical Company Limited

20110098347 - Phosphorous binder for treatment of kidney disease: The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products... Agent: Biolink Life Sciences, Inc.

20110098348 - Cannabis sativa plants rich in cannabichromene and its acid, extracts thereof and methods of obtaining extracts therefrom: The present invention relates to plants producing, as their major cannabinoid cannabichromenic acid (CBCA) or its neutral (decarboxylated) form cannabichromene (CBC), hereafter jointly referred to as CBC(A). It additionally relates to: • A botanical material obtainable from said plants; • A botanical raw material (BRM), • An extract including a... Agent: Gw Pharma Limited

20110098349 - Cathechins for the treatment of systemic aa amyloidosis: A method of treating an amyloid disease characterized by AA amyloid fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins. The therapeutic amount of the catechin is selected for efficacy in treating AA amyloid fibrillogenesis in a mammalian... Agent:

20110098350 - Substituted cyclohexylidene-ethylidene-octahydro-indene compounds: Novel substituted cyclohexylidene-ethylidene-octahydro-indene compounds and compositions comprising the same are described. The compounds exhibit profound anti-proliferative effects, in comparison to other compounds known for their anti-cancer and anti-hyperproliferative ability. Methods of use of such compounds and compositions are described for treating a variety of cancers, inflammatory and other hyperproliferative diseases... Agent:

20110098351 - Lactone compounds which can be used as antioxidant agents in pharmaceutical, cosmetic or food compositions and their method of preparation: The subject of the present invention is specific lactone compounds which can be used as antioxidant agents in pharmaceutical or cosmetic compositions or in food products, the said compounds containing a naphthalene ring onto which two lactone units are grafte.... Agent: Centre National De La Recherche Scientifique

20110098352 - N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20110098353 - Compounds for imaging and therapy: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X′, Y, L1′, R1′ and R2′ are as defined herein, is useful in medical imaging and therapy.... Agent:

20110098355 - Method of preparing a latanoprost ophthalmic solution and resulting solution: A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method,... Agent:

20110098354 - Method of preparing a latanoprost ophthalmic solution and the resulting solution: A method of solubilizing an analog active agent of the prostaglandin F2α, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method,... Agent:

20110098356 - Production and purification of esters of polyunsaturated fatty acids: The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can... Agent: Martek Biosciences Corporation

20110098357 - Vaginal suppository comprising lactic acid: The present invention relates to a vaginal suppository comprising an inert vehicle and lactic acid or a salt thereof for the treatment and/or prophylaxis of disorders in the urogenital tract. It also relates to the use of such a suppository for the production of a medicament for the treatment and/or... Agent:

20110098358 - Human beta3 adrenergic receptor ligand, and food or pharmaceutical product containing the same: A human adrenergic β3 receptor ligand containing the following 3 components: (A) an unsaturated fatty acid having not less than three double bonds or a pharmaceutically acceptable salt thereof, (B) an unsaturated fatty acid having one or two double bond(s) or a pharmaceutically acceptable salt thereof; and (C) a saturated... Agent: Ricom Corporation

20110098359 - Compositions and methods for treatment of glaucoma: A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol... Agent: Stellenbosch University

20110098360 - Adamantane derivative for inhibiting toxicity of amyloid oligomer: Disclosed is a pharmaceutical composition containing a compound useful for inhibiting neurotoxicity caused by beta amyloid. The pharmaceutical composition of the present disclosure contains 1,3,5,7-tetrakis(aminomethyl)adamantane, an analogous compound thereof or a salt thereof as an active ingredient. The inventors have studied methods for reducing the toxicity of beta amyloid oligomers... Agent: Nanodiamond, Inc.

20110098361 - Composition to enhance the bioavailability of curcumin: A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric.... Agent:

20110098362 - Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2)... Agent:

20110098363 - Amphiphilic molecules with a triazine core: The present invention is directed to chemical compounds of formula (I) wherein A1 is selected from the group consisting of alkyl, aryl, alkylaryl and (formula A), A2, A3, A4, A5 and in case A1 is (formula A) also A6 and A7 comprise a polymer selected from the group consisting of... Agent: Basf Se

20110098364 - Novel inverse latices based on fatty alcohol ethers, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising: Novel inverse latices based on fatty alcohol ethers of formula R1—O—R2 (I) in which R1 and R2 represent, independently from one another, a linear or branched alkyl radical comprising from 5 to 18 carbon atoms; and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising them.... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20110098365 - Salt product: A method of preparing a salt product comprises the steps of: (i) providing a mixture which comprises salt dissolved in a solvent, said mixture further containing an organic material that is solid under ambient temperature conditions; and (ii) atomising said mixture and evaporating said solvent to produce a salt product... Agent:

20110098366 - Pharmaceutical preparation in containers that are pervious to water vapor and have improved stability: The present invention relates to a pharmaceutical preparation, comprising a mixture of at least one pharmaceutical active ingredient, at least one alcohol component and at least one triglyceride component, in a plastic container, characterized in that the plastic has a water vapour permeability of no more than 3.0 g/m2/24 h... Agent:

  
04/21/2011 > patent applications in patent subcategories. category listing, related patent applications

20110092412 - Method of producing tat-hoxb4h: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the... Agent: Taiwan Advance Bio-pharm Inc.

20110092411 - Recombinant lactoferrins, methods of production from plants and uses thereof: The invention concerns the use of a recombinant nucleotide sequence containing a DNAc coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said DNAc, in particular a transcription promoter and terminator identified... Agent:

20110092413 - Albumin-fused kunitz domain peptides: The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins... Agent: Novozymes Biopharma Dk A/s

20110092414 - Composition for treating virus infection disease comprising jab1: Disclosed is a composition for treating or preventing a viral infection or associated disease comprising a Jab1 protein, a nucleic acid having a nucleotide sequence coding for a Jab1 protein or a recombinant virus expressing a Jab1 protein.... Agent: Sungkyunkwan University

20110092415 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Labaoratories

20110092416 - Vitamine b12 - peptide conjugates for oral delivery: Compositions containing a therapeutic peptide covalently linked to Vitamin B12 at the 5′-hydroxyl group of the ribose moiety of α-ligand are described. The length of the linkage is optimized so that the biological activity of both the Vitamin B12 and the therapeutic peptide is maintained. Therapeutic peptides for conjugation with... Agent:

20110092417 - Leptin fusion proteins: The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.... Agent: Asterion Limited

20110092418 - Chimeric relaxin polypeptides comprising an a and b chain derived from different relaxin family peptides: Provided herein are modified relaxin polypeptides wherein the B chain comprises the core amino acid sequence CGR-XXX-R-XX-I/V-XX-CG (SEQ ID NO:1), where X is any amino acid. Also provided are modified relaxin polypeptides comprising at least an A and a B chain, wherein the A and B chains are derived from... Agent: Floreky Institute Of Experimental Physiology And Medicine

20110092419 - Protease-stabilized insulin analogues: The present invention relates to novel insulin analogues comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogues; insulin preparations containing the insulin analogues of... Agent: Novo Nordisk A/s

20110092420 - Selenium containing modifying agents and conjugates: The invention relates to a modifying agent comprising a water soluble polymer, wherein the water soluble polymer comprises at least one reactive selenium group, said reactive selenium group being capable of reacting with a thiol group thereby forming an —Se—S— bond. Furthermore, the invention relates to a method for producing... Agent: Lek Pharmaceuticals D.d.

20110092421 - Methods for generating new hair follicles, treating baldness, and hair removal: The present invention provides methods of treating baldness in a subject and generating new hair follicles, comprising epidermal disruption and administration of a compound that promotes a differentiation of an uncommitted epidermal cell into a hair follicle cell. The present invention also provides methods for hair removal and inducing hair... Agent:

20110092422 - Elastin based growth factor delivery platform for wound healing and regeneration: The invention is based on the discovery of a potent growth factor delivery system by creating a fusion polypeptide that includes two portions: (i) keratinocyte growth factor protein, and (ii) an elastin-like peptide. This chimera can be administered directly to a wound site, accelerating recovery.... Agent: The General Hospital Corporation

20110092423 - Inhibitors of akt activity: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Glaxosmithkline, LLC

20110092424 - Production of glucagon like peptide 2 and analogs: GLP-2 peptides and analogs thereof are produced in high yield and with desired, authentic termini by isolation from a GLP-2 peptide multimer in which at least two units of GLP-2 peptide are coupled through a linker that presents an N-terminal acid cleavage site and a C-terminal enzyme cleavage site. In... Agent: Nps Pharmaceuticals, Inc.

20110092425 - Method of drug delivery for bone anabolic protein: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be... Agent: Ipsen Pharma S.a.s

20110092426 - Oral calcitonin compositions and applications thereof: The present invention relates to compositions for the oral delivery of pharmacologically active calcitonin, to methods of synergistically enhancing the biological effects of orally administered calcitonin with D type vitamins and calcium, and to methods of treating and/or preventing disease in mammals, particularly humans, by orally administering calcitonin compositions in... Agent: Novartis Ag

20110092427 - Polypeptide and pharmaceutical composition containing the polypeptide: Disclosed is a novel polypeptide which can inhibit angiogenesis. Also disclosed is use of the polypeptide. The polypeptide comprises at least one amino acid sequence selected from the amino acid sequences depicted in SEQ ID NOs: 1-3, is composed of 120 or less amino acid residues, and has an anti-angiogenic... Agent: Kurume University

20110092428 - Detecting and controlling abnormal hematopoiesis: A method of detecting abnormal hematopoiesis in a subject based on abnormal expression of ZFP36L2, a method of controlling hematopoiesis in a subject altering the level or activity of ZFP36L2 protein in the subject, a method of screening for compounds that modulate hematopoiesis based on changes to ZFP36L2 expression, and... Agent: The United States Of America,as Represented By The Secretary ,department Of Healthyand Human Service

20110092429 - Compositions and methods for producing gamma-carboxylated proteins: The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and γ-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated... Agent:

20110092430 - Method and compound for the treatment of valvular disease: The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide/phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment... Agent: Montreal Heart Institute

20110092431 - Skin aging-inhibiting peptide: The present invention provides a peptide and a composition which are suitable for oral ingestion, and which have a skin aging-inhibiting activity, a collagen-production promoting activity, an epidermal turnover promoting activity, and a cutaneous cell-proliferating effect. The present invention also provides a medicament and a functional food which have a... Agent: Calpis Co., Ltd.

20110092432 - Vascular aging inhibitor and anti-aging formulation: A vascular aging inhibitor includes a low molecular weight collagen derived from fish skin as an essential component, wherein the weight average molecular weight of the low molecular weight collagen derived from fish skin is approximately 3,000.... Agent:

20110092436 - Compounds for treating symptoms associated with parkinson's disease: The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ).... Agent: Affiris Ag

20110092433 - Fgf9-related methods for treating anxiety: The present application relates to the treatment of anxiety in a subject. The invention provides novel diagnostic markers and assays, as well as agents and compounds useful for treating patients who suffer from mental illnesses and anxiety disorders.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110092434 - Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders: The present invention relates to the use of at least one compound comprising the amino acid sequence: (X1)nX2X3PVX4X5X6(X7)m (Formula I), wherein X1 is any amino acid residue, X2 is an amino acid residue selected from the group consisting of aspartic acid (D) and glutamic acid (E). X3 is any amino... Agent: Affiris Ag

20110092435 - Treatment of parkinson's disease: Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used... Agent: Cedars-sinai Medical Center

20110092437 - Use of cyclic depsipeptides to inhibit kallikrein 7: The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7.... Agent:

20110092438 - Composition for external application comprising transcription factor decoy as active ingredient: The present invention provides an external preparation composition of transcription factor decoy of good skin permeability, the composition comprising a transcription factor decoy dissolved in a fatty acid-based ionic liquid obtained from a fatty acid having 2 to 20 carbon atoms and an organic amine compound having 4 to 12... Agent: Medrx Co., Ltd.

20110092439 - Method of promoting wound healing: The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.... Agent:

20110092440 - Method of regulating cell growth using a proteasome inhibitor: This invention provides methods and pharmaceutical compositions for regulating cell growth or inducing apoptosis in a cell, particularly a mammalian tumor cell. Specifically, the invention provides methods for inducing apoptosis in a tumor cell comprising contacting the tumor cell with a proteasome inhibitor and a thiazole antibiotic, particularly each in... Agent: The Board Of Trustees Of The University Of Illinois

20110092441 - Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component: The present invention relates to a cell-permeable endostatin recombinant protein in which a macromolecule transduction domain (MTD) is fused to an angiogenesis inhibitor (angiogenesis inhibitor) endostatin; a polynucleotide encoding the cell-permeable endostatin recombinant protein; an expression vector for the cell-permeable endostatin recombinant protein; and a pharmacological composition for an anti-cancer... Agent: Jo Daewoong

20110092442 - Anticancer agent containing bl-angiostatin: An anticancer agent containing BL-angiostatin as an active ingredient; and a process for producing the same. Also a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of BL-angiostatin.... Agent: Ttc Co., Ltd

20110092443 - Cyclosporine compositions for enhancing nail growth: The present invention is directed to cyclosporine compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth... Agent: Allergan, Inc.

20110092444 - Large scale preparation of alpha-1 proteinase inhibitor and use thereof: A pharmaceutical preparation containing a purified, active API in the form of a ready to use sterile solution that optionally includes an excipient, diluent or a carrier. At least 90% to 95% of the API is active and is present at a concentration between about 1% to about 10%. The... Agent:

20110092445 - Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses: The present invention relates to an amyloid β peptide analogues comprising an amino acid sequence or a peptidomimetic thereof, wherein the sequence (i) forms a loop, (ii) has at least 66% identity to the amino acid sequence of native Aβ peptide or a portion thereof, (iii) comprises at least 6... Agent: Abbott Laboratories

20110092446 - Compositions and methods for treatment of trauma: The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may,... Agent:

20110092447 - Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions: Compounds can be used to act as inhibitors of enzymes having histone deacetylase activity for the medical therapy of conditions which predispose a person for the development of a disease, such as but not limited to cancer, inflammatory or metabolic diseases. Such conditions are linked to genetically inherited mutations of... Agent:

20110092450 - Method of enhancing the mobilization of hematopoietic stem cells using tat-hoxb4h: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the... Agent: Taiwan Advance Bio-pharm Inc.

20110092448 - Peptide conjugate for oral delivery of hydrophilic peptide analgesics: The present invention provides a method of improving the oral delivery of a parent peptide, comprising the step of linking the parent peptide to an added peptide to form a conjugate which has greater oral bioavailability than the parent molecule alone, the added peptide comprising a balance of hydrophobic and... Agent: Metabolic Pharmaceuticals Limited

20110092449 - Treatment of fibrotic conditions: Compositions, articles, devices and methods for the treatment of fibrosis and fibrotic diseases, disorders, and conditions in humans and non-human animals.... Agent:

20110092569 - Administration of exogenous mi/sirna: Certain genes controlled by endogenous miRNA are actually upregulated upon the transfection of exogenous mi/siRNA. Based on this, methods of determining whether administration of mi/siRNA will have a deleterious effect by upregulating certain genes are provided. Comparison of sequences of exogenous mi/siRNA allows selection of exogenous miRNA to be administered... Agent: Sloan-kettering Institute For Cancer Research

20110092567 - Cannabinoid 2 (cb2) receptor gene promoter and unique rna transcripts in b cells and methods of use: Cannabinoid receptor 2 (CB2) is expressed in B lymphocytes and is involved in immune regulation. Mouse splenic B cells express three CB2 transcripts utilizing two different first exons. Human peripheral blood B cells express one CB2 transcript utilizing one first exon. Alignment of sequenced RACE products to either the mouse... Agent: University Of South Florida

20110092571 - Compositions and methods for sirna inhibition of icam-1: RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can... Agent: The Trustees Of The University Of Pennsylvania

20110092565 - Method of treating neurodegenerative disease: Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells.... Agent: Alnylam Pharmaceuticals, Inc.

20110092573 - Modification of myd88 splicing using modified oligonucleotides: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.... Agent: Isis Pharmaceuticals, Inc.

20110092572 - Modulation of growth hormone receptor expression and insulin-like growth factor expression: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of... Agent: Isis Pharmaceuticals, Inc.

20110092568 - Modulation of mlck-l expression and uses thereof: In various aspects and embodiments the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases. Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for... Agent: The Board Of Trustees Of The University Of Illinois

20110092574 - Mrna cap analogs: Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally,... Agent:

20110092570 - Oligomeric compounds comprising tricyclic nucelosides and methods for their use: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize... Agent:

20110092566 - Treatment of cancer with aldose reductase inhibitors: Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be small molecules such as fidarestat or siRNA. Also, methods of treating breast and prostate cancers... Agent:

20110092577 - Inositol pyrophosphates determine exocytotic capacity: The invention provides reagents and methods for treating type II diabetes, as well as methods for identifying compounds for treating type II diabetes.... Agent: Biocrine Ab

20110092575 - Sirna of human osteopontin: The present invention provides siRNA for suppressing expression of human osteopontin in a more specific and strong manner, and a composition and a medicine comprising the same.... Agent: Assignment For Published Patent Application Gene Techno Science Co., Ltd.

20110092576 - Synthetic phosphodiester oligonucleotides and therapeutical uses thereof: A composition of phosphodiester oligonucleotides of various defined sizes has been created that mimics the effects of defibrotide. The composition essentially consists of mixtures of synthetic phosphodiester oligonucleotides comprising Nmers ranging from 40 mers to 65 mers. The phosphodiester oligonucleotides are preferably heteropolymers composed of either A, G, C, and... Agent: Gentium Spa

20110092451 - Nucleotide analogues with quaternary carbon stereogenic centers and methods of use: The present invention comprises compounds useful as antiviral or antitumor agents. The compounds comprise nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moeities with quaternary centers at the 3′ position. The nucleotide analogues can be used to inhibit cancer or viruses. Accordingly, the compounds of the present invention are useful for... Agent: Institut De Recherches Cliniques De Montreal

20110092452 - Compositions and methods for diagnosing and treating pancreatic cancer: The present invention provides compositions and methods for treating and diagnosing the presence of solid tumor stem cells in a patient (e.g., based on the presence of c-Met). In certain embodiments, the presence or absence of solid tumor stem cells (e.g., pancreatic solid tumor stem cells) can be determined through... Agent: The Regents Of The University Of Michigan

20110092453 - Treatments and prevention of hydrocephalus: The present invention relates to the prevention or treatment of hydrocephalus. In one embodiment, the invention includes the use of one or more bioavailable folate derivatives, or salts thereof, for the prevention or treatment of hydrocephalus. Examples of more bioavailable folate derivatives that may be used include any combination of:... Agent: The University Of Manchester

20110092454 - Methods for treating mycoplasma related conditions in livestock: The present invention provides methods and related kits for treating or preventing a mycoplasma-related bovine disease. In one aspect, for example, a method for treating or preventing a mycoplasma-related bovine disease may include administering to a bovine a therapeutically effective amount of a steroid or a pharmaceutically acceptable salt thereof,... Agent:

20110092455 - Method and composition for the control of arthropods: The present invention relates to the use of certain siloxanes and mixtures thereof in the control of arthropods such as insects and arachnids, and in particular ectoparasites, such as head lice.... Agent:

20110092459 - Alpha helix mimetics and methods relating thereto: Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic... Agent: Prism Biolab Corporation

20110092456 - Methods of increasing camp levels and uses thereof: The present invention shows that cilostazol, a phosphodiesterase 3 inhibitor has additional beneficial effects to atorvastatin on myocardial remodeling by inducing and preserving eNOS phosphorylation. The present invention demonstrates a cardioprotective effect of Cilostazol indicating the therapeutic potency of this drug. In addition, the present invention demonstrates that the additional... Agent:

20110092457 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent:

20110092458 - Use of (r)-penciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases: A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a... Agent:

20110092460 - Cyclopropyl polymerase inhibitors: m

20110092461 - Pyridyl inhibitors of hedgehog signalling:

20110092462 - Use of high-dose oxazaphosphorine drugs for treating immune disorders: This disclosure relates, at least in part, to methods of eliminating adverse immune reactions in a subject in need thereof including those associated with autoimmune diseases, allergic reactions and transplant rejection, including administration of a lymphocytotoxic non-myeloablative amount of a oxazaphosphorine drug to the subject.... Agent: The Johns Hopkins University

20110092463 - Combination for use in the treatment of inflammatory disorders: There is provided combination products comprising (a) pemirolast, or a pharmaceutically-acceptable salt or solvate thereof; and (b) a compound that inhibits the formation and/or action of angiotensin II, or a pharmaceutically-acceptable salt or solvate thereof. Such combination products find particular utility in atherosclerosis and related conditions.... Agent:

20110092464 - Neurogenesis by modulating angiotensin: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.... Agent: Braincells Inc.

20110092465 - Monomeric pyrophosphate complexes and methods of treatment using the complexes: The present invention involves pyrophosphate bridged coordination complexes and the treatment of medical conditions, such as cancer, using the pyrophosphate bridged coordination complexes. The pyrophosphate bridged coordination complexes include four new compounds, [Co(phen)2(H2P2O7)].4H2O (1.4H2O), [Ni(phen)2(H2P2O7)].8H2O (2.8H2O), [Cu(phen)(H2O)(H2P2O7)], and {[Cn(phen)(H2O)(P2O7)] [Na2(H2O)8]}.6H2O(4.14H2O) found effective for treating cancer cells. The pyrophosphate bridged coordination... Agent: Syracuse University

20110092466 - Method for protecting soybeans from being infected by fungi: e

20110092467 - 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds: Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included.... Agent: Trustees Of Tufts College

20110092468 - Pharmaceutical calcimimetics: This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the... Agent: Concert Pharmaceuticals Inc.

20110092470 - Method of treating men with erectile dysfunction: A method of treating male sexual dysfunction or erectile dysfunction by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with another agent useful for treating erectile... Agent:

20110092469 - Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of respiratory illness in muscular dystrophy: The present invention relates to 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone) for treating and/or preventing respiratory illness associated with certain forms of muscular dystrophy.... Agent: Santhera Pharmaceuticals (schweiz) Ag

20110092471 - Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis: The subject matter of this application relates to the combination of ciclesonide with an antihistamine.... Agent: Nycomed Gmbh

20110092472 - Enzymatic process for obtaining 17 alpha- monoesters of cortexolone and/or its 9,11- dehydroderivatives: e

20110092473 - Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties: This invention describes compounds of Structures 1, 2, and 3 and their use as allosteric modulators of the GABA receptor chloride ionophore complex to alleviate stress, anxiety, mood disorders, seizures, depression, treatment of drug and alcohol abuse, memory, premenstrual disorders, and neural system damage.... Agent: Us Gov By The Sec. Of Dept. Of Health & Human Serv.

20110092475 - 2-substituted-ethynylthiazole derivatives and uses of same: i

20110092476 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof:

20110092477 - Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines: Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of... Agent: 3m Innovative Properties Company

20110092474 - Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine h4 receptor: Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Agent: Janssen Pharmaceutica Nv

20110092478 - Diazabenzo[de] anthracen-3-one compounds and methods for inhibiting parp: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.... Agent: Eisai Inc.

20110092479 - Pyrazole [3, 4-b] pyridine raf inhibitors: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are... Agent: Genentech, Inc.

20110092481 - Quinoline or isoquinoline substituted p2x7 antagonists: The present invention is related to novel compounds of formula (I) having P2X7 antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans. (I)... Agent: Janssen Pharmaceutica Nv

20110092480 - Substituted heterocyclic derivatives and their pharmaceutical use and compositions: Compounds of the general Formula I, wherein X1, X2, X3, X4, X5, X6, X7, R1, R2, R4, R5, R6, R7, R8, R9, R10, Y1, n, m, p and q are defined as above, their preparation and their use as antimicrobial agents.... Agent: Pfizer Inc.

20110092482 - Methods and compositions: The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of nociceptive pain. More particularly, the present invention provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of... Agent: Relevare Aust. Pty Ltd

20110092483 - Screening molecules with anti-prion activity: kits, methods and screened molecules: A kit and a method for identifying compounds having anti-prion activity are provided. The kit comprises a yeast of phenotype [PSI+]; an antibiogram; and a prion curing agent in a sub-effective dose, wherein the yeast has the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene. Compounds and... Agent: Universite De Poitiers

20110092484 - Therapeutic or prophylactic agent for cerebral aneurysm: k

20110092485 - Substituted benzoazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.... Agent: Array Biopharma, Inc.

20110092486 - Ih channel inhibitors for the promotion of wakefulness: The present invention relates to use of an Ih channel inhibitor for the manufacture of a medicament for the promotion of wakefulness in a subject in need thereof, in particular, wherein the subject is suffering from excessive sleepiness which may result from a sleep disorder.... Agent:

20110092487 - Novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza-bicyclo[3.3.1]-nonane-3-carboxylic acid ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 3,8-diaza-bicyclo[3.2.1]octane-and 3,9-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid ester derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. Formula (I).... Agent: Neurosearch A/s

20110092488 - Quninoline methanol compounds for the treatment and prevention of parasitic infections: Malaria is responsible for 1-2 million deaths and 300-500 million clinical cases annually and is an ever present problem for the military, tourists and business travelers. Mefloquine is known and used for malaria prophylaxis. However it is associated with neurological effects. The present invention is directed to providing new and... Agent:

20110092489 - 3-aryl-substituted quinazolones, and uses thereof: l

20110092491 - Compounds and compositions as inhibitors of receptor tyrosine kinase activity: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with cSRC, Lck, FGFR3, Flt3, TrkB, Bmx, and/or PFGFRα kinase activity.... Agent: Novartis Ag

20110092490 - Pyrimidines, triazines and their use as pharmaceutical agents: A compound of formula (I) and its pharmaceutically acceptable salts or solvates and physiologically hydrolysable, solubilising or immobilisable derivatives wherein: Ar is a 5-membered heteroaryl ring wherein X1 and X2 are one or two heteroatoms or Ar is a 6-membered aromatic ring, wherein heteroatoms are selected from S, O, N,... Agent: The University Of Nottingham

20110092492 - Imidazo compounds: Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R1, R2, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in... Agent:

20110092493 - Dose-controlled transdermal promethazine compositions and methods of use: The current invention provides formulations for transdermal delivery of promethazine which achieve delivery of the drug with consistent plasma levels. The topical formulations of the invention are superior to both rectal suppositories and oral dosage forms in that variable blood levels, first-pass metabolism, unpredictable peaks in blood levels, and variable... Agent:

20110092494 - Tricyclic tetrahydroquinoline antibacterial agents: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.... Agent: Pharmacia & Upjohn Company

20110092495 - Compounds for the treatment of multi-drug resistant bacterial infections: The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.... Agent: Astrazeneca Ab

20110092496 - Thiophene compounds and thrombopoietin receptor activators: A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.... Agent: Nissan Chemical Industries, Ltd.

20110092498 - 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors: Compounds of the formula (I), in which R1, R2, R3, R3′, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110092497 - Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases: m

20110092499 - N-containing heterocyclic compounds: The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated... Agent: Ym Biosciences Australia Pty Ltd

20110092500 - Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment: The invention provides pharmacological compositions comprising a stimulator or activator of the soluble guanylate cyclase (sGC) either alone or in combination for the treatment of hearing impairment i.e. hearing loss and tinnitus.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110092502 - Diaminothiazoles useful as axl inhibitors: Diaminothiazoles and pharmaceutical compositions containing them are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the diaminothiazoles in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110092501 - Novel inhibitors: a

20110092504 - Inhibitors of pi3 kinase: The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.... Agent: Amgen Inc.

20110092503 - Quinoline derivatives as axl kinase inhibitors: Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment... Agent:

20110092505 - Organic compounds: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.... Agent:

20110092506 - Trisubstituted amine compound: wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R1 is an optionally substituted alkyl group, and the like; and R2 is an optionally substituted amino group, and the like;... Agent:

20110092507 - Process for preparing r-(+)-3-morpholino-4-(3- tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole: The present invention provides a process for preparing optically active timolol. The process comprises the following steps. Firstly, reacting 3-hydroxy-4-morpholino-1,2,5-thiadiazole with an optically active epichlorohydrin in the presence of a solvent system, which has a first volume and a catalyst optionally in the presence of a suitable base to obtain... Agent:

20110092508 - Biomarkers of tumor pharmacodynamic response: The present invention provides novel biomarkers, and methods of using said biomarkers, for assessing the efficacy of a treatment regimen for treating cancer in a subject, particularly for treating cancer via Hsp90 inhibition. The present invention also provides methods of identifying test agents capable of treating cancer, particularly in the... Agent: Novartis Ag

20110092509 - Pharmaceutical composition for prevention or treatment of disease associated with tear reduction: The present invention provides pharmaceutical compositions for the prevention or treatment of diseases associated with decrease in tear such as dry eye, dry disorders of cornea and conjunctiva, disorders of the keratoconjunctival epithelium, syndrome with decrease in tear secretion, xerophthalmia, dry eye due to aging, ophthalmopathy in Stevens-Johnson syndrome, ophthalmopathy... Agent: Kissei Pharmaceutical, Co. Ltd.

20110092510 - Dpp-iv inhibitors for use in the treatment of nafld: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).... Agent: Boehringer Ingelheim International Gmbh

20110092511 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity especially Akt1 by administering the compound... Agent:

20110092512 - New hsl inhibitors useful in the treatment of diabetes: e

20110092513 - 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases: The present invention relates to novel 5,6-disubstituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the manufacture of a medicament.... Agent: Abbott Gmbh & Co. Kg

20110092514 - Compounds with anti-cancer activity: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders.... Agent: Canbas Co., Ltd.

20110092515 - Melt granulation process: A process for preparing solid dosage forms that contain a quinoline compound. The process, for example, provides for the inventive use of an extruder, especially a twin screw extruder, to melt granulate the quinoline compound with a granulation excipient.... Agent:

20110092516 - 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases: The present invention relates to novel 5-halogen-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.... Agent: Abbott Gmbh & Co. Kg

20110092517 - Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases: Provided herein are methods for treatment, prevention, or amelioration of one or more symptoms of a disease or condition related to disorders of insulin and/or glucose metabolism, inflammatory conditions, mitochondrial disease, muscle disorders, or pulmonary disorders, involving administering a PPARδ agonist or a pharmaceutical composition comprising a PPARδ agonist. In... Agent: Cerenis Therapeutics S.a. & Nippon Chemiphar Co., Ltd.

20110092518 - Antifouling compounds and use thereof: The present invention relates to the use of compounds which have the following general formula (I), wherein R1 and R2 are independently selected from optionally substituted aryl, optionally substituted C1 to C12 alkyl and H; and R3 and R4 are independently selected from hydroxy, optionally substituted C1 to C6 alkyl,... Agent: Maritime And Port Authority Of Singapore

20110092519 - 5,7-disubstituted thiazolo[4,5-d]pyrimidines as chemokine inhibitors: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1... Agent: Astrazeneca Ab

20110092520 - Process for producing bicycloaniline derivatives: The present invention relates to a process for producing a hydrate of 3-(2,6-dichlorophenyl)-4-imino-7-[(2′-methyl-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinolin]-7′-yl)amino]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (Compound A) or of a pharmaceutically acceptable salt of Compound A and a crystalline form of Compound A or of a pharmaceutically acceptable salt of Compound A, which are useful in the field of treatment of various... Agent:

20110092523 - Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).... Agent: Alcon Research, Ltd.

20110092521 - Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases: The invention relates to treating a disease or condition in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase (MTAP) and/or 5′-methylthioadenosine nucleosidase (MTAN). The invention particularly relates to the co-administration of 5′-methylthioadenosine (MTA), or a prodrug of MTA, with one or more MTAP/MTAN inhibitors. Included among the diseases treatable are... Agent:

20110092522 - Wound and skin care procuts: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.... Agent: Kimberly-clark Worldwide, Inc.

20110092524 - Agent for enhancing corneal epithelial barrier function: The invention relates to a pharmacological action of a compound which functions as a PPARγ agonist on the barrier function of the corneal epithelium. A PPARγ agonist such as rivoglitazone, DRF-2593, GW-544 or BMS-298585 exhibits an excellent effect of enhancing the corneal epithelial barrier function in a test for enhancement... Agent: Santen Pharmaceutical Co., Ltd.

20110092525 - Gabaa receptor modulators: The resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.... Agent:

20110092526 - Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-beta-hsd1 826: e

20110092527 - 4 (pyrrolopyridinyl)pyrimidin-2-ylamine derivatives: Compounds of the formula (I), in which R1, R2, R3, R4 and R5 have the meanings indicated in claim 1, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours... Agent: Merck Patent Gesellschaft

20110092528 - Piperidinyl compounds that selectively bind integrins: The invention is directed to piperidinyl compounds that selectively bind integrin receptors and methods for treating an integrin mediated disorder.... Agent:

20110092529 - 1,2,4-triazole derivatives and their use as oxytocin antagonists: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc.

20110092530 - Cyclopamine tartrate salt and uses thereof: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides highly water-soluble analogs of cyclopamine that are potent, hedgehog signaling inhibitors less toxic than cyclopamine. The compounds of the present invention are particularly useful in treating cancers associated with hedgehog signalling.... Agent:

20110092531 - Novel spiropiperidine compounds: e

20110092532 - Apomorphine pharmaceutical dosage security system: An apomorphine pharmaceutical dosage security system embodied in multiple dosage forms including oral dosage forms, transdermal delivery patches, nasal delivery forms, and transdermal dosage forms. Within the present invention is an amount of apomorphine adapted to be bioavailable to a degree sufficient to cause emesis or severe nausea when an... Agent:

20110092533 - Compounds for binding to er alpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases... Agent: Stc. Unm

20110092534 - Ammosamides as anticancer agents: A compound having the general the general structure I is provided: (Formula I), wherein Z is a substituent selected from a group consisting of S and O; X is a substituent selected from a group consisting of Cl, Br, I, OH and NH2; each of R1 and R2 is a... Agent: The Regents Of The University Of California

20110092535 - Novel epilepsy treatment: The present invention resides in the use of a 5-HT3 receptor antagonist as medicament for the treatment of temporal lobe epilepsy associated with hippocampal sclerosis (TLE-HS) in a human patient. Tropisetron or Dolasetro are the preferred compounds.... Agent:

20110092537 - 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases... Agent: Ac Immune S.a.

20110092538 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Plexxikon Inc.

20110092536 - Novel anti-infectious derivatives, method for the production thereof, pharmaceutical compositions containing same and uses of said derivatives in treatment: The invention relates to bi-substrate inhibitor molecules associating (i) a pyridine, pyridinium or dihydropyridine-type structure allied to active metabolites of isoniazide, or related structures, and (ii) a hydrophobic substituent. The invention also relates to the method for producing said molecules, to the pharmaceutical compositions containing said molecules, and to the... Agent: Universite Paul Sabatier Toulouse Iii

20110092539 - Indane derivatives as ampa receptor modulators: The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for... Agent:

20110092540 - Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands: The invention relates to compounds having pharmacological activity towards the 5-HT6; receptor, and more particularly to some N-phenyl-2,3-dihydroimidazol[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.... Agent: Laboratorios Del Dr. Esteve, S.a.

20110092541 - Novel compositions for preventing and/or treating degenerative disorders of the central nervous system: The present invention provides novel compounds as well as compositions and methods using the same for preventing and/or treating degenerative disorders of the central nervous system. In particular, the present invention provides methods for preventing and/or treating Parkinson's disease.... Agent: Amicus Therapeutics, Inc.

20110092542 - Methods for treating spinal cord injury with a compound that inhibits a ncca-atp channel: The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, antagonists of the NCCa-ATP channel are contemplated. The compositions are used to prevent cell death and to treat secondary damage associated with spinal... Agent:

20110092543 - Wound and mucosa antiseptic based on bispyridiniumalkanes: The invention relates to an antimicrobially effective composition which comprises a) 0.001 to 1% by weight of bispyridiniumalkane, b) humectant and c) water. The composition has an osmolality of from 230 to 350 mOsmol/kg and is free from surfactant. It is used as wound and mucosa antiseptic.... Agent: L'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude

20110092544 - Fungicidal pyridines: e

20110092545 - Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding: Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and related compounds.... Agent: Foldrx Pharmaceuticals, Inc., A Massachusetts Corporation

20110092546 - Substituted benzimidazoles for neurofibromatosis: The present invention relates to the use of BENZIMIDAZOLE DERIVATIVES for the preparation of a drug for the treatment of neurofibromatosis.... Agent: Novartis Ag

20110092547 - Chemical compounds 979: e

20110092548 - Method for treating/preventing disease using cognitive ability of cerebrum and pharmaceutical: An object of the present invention is to develop a method of enhancing the cognitive ability of a brain to fundamentally cure a disease. It has been found out that, by using a medicament for treating or preventing a disease including a combination of a major tranquilizer, and vitamin C... Agent:

20110092549 - Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone: A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed.... Agent: Solanan, Inc.

20110092550 - Combinations of imazalil and hydroxypyridones: The present invention relates to combinations of imazalil, or a salt thereof, and hydroxypyridones which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more hydroxypyridones selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone,... Agent:

20110092551 - Dual-acting imidazole antihypertensive agents: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for... Agent: Theravance, Inc.

20110092552 - Treatment and prevention of major adverse cardiovascular events or major coronary events by administering omega-3 fatty acids: Omega-3 fatty acid compositions comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are provided, where the compositions are useful for treating, reducing the occurrence of, or preventing major adverse cardiovascular events or major coronary events in patients who have established cardiovascular disease without prior myocardial infarction, preventing their further progression,... Agent: Pronova Biocare As

20110092553 - Substituted azole derivatives, compositions, and methods of use: The present invention provides azole derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and their use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for... Agent: Transtech Pharma, Inc.

20110092554 - 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders: The present disclosure relates to novel 1,3,5 tri-substituted benzenes of general formula (I), (II) or (III) and the use of such compounds in the treatment of diseases associated with the deposition of -amyloid in the brain.... Agent:

20110092555 - Thiazolidinedione compound: A compound which is 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]benzyl}thiazolidine-2,4-dione hydrochloride, in crystal form wherein a powder x-ray diffraction pattern obtained by irradiation with a Cu Kα line shows main peaks at interplanar spacings d=14.29, 7.12, 5.34, 4.97, 4.74, 3.95, 3.85, 3.75, 3.55, 3.51, 3.15, 2.84, 2.76, 2.52 and 2.37.... Agent: Daiichi Sankyo Company, Limited

20110092556 - Plant disease controlling composition and method for controlling plant disease: There is provided a plant disease controlling composition comprising at least one compound (A) selected from the group consisting of metconazole, bromuconazole and epoxyconazole, as well as a compound represented by the formula (I): as active ingredients. Also provided is a method for controlling a plant disease, which comprises applying... Agent: Sumitomo Chemical Company, Limited

20110092557 - Neuraminidase inhibitors and compositions and methods related thereto: The present invention provides compounds comprising amino acid R groups, compositions comprising the same, and methods of inhibiting neuraminidase and/or treating influenza, Pseudomonas aeruginosa, or Bacteroides fragilis infection in a mammal.... Agent: Influmedix Inc.

20110092558 - Novel microbiocides: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection, Inc.

20110092559 - Pyrrole and pyrazole daao inhibitors: m

20110092560 - Topical composition for controlling ectoparasites in dogs and cats: This invention describes a new topical formulation (spot-on) for controlling ectoparasites in cats and dogs, which comprises the active ingredient Fipronil and/or the derivates and salts thereof, as well as antioxidants and a suitable vehicle. The use of an organic solvent acting as the transdermal carrier provides this product with... Agent: Ceva Sante Animale Sa

20110092561 - Benzoisoindole derivatives for the treatment of pain: i

20110092562 - Method for wetting a powder containing benzoyl peroxide: Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing water and one or more water-soluble organic solvents in a concentration sufficient to reduce the surface tension of the liquid to 64 dynes/cm or less.... Agent:

20110092563 - Statin and omega-3 fatty acids for lipid therapy: A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-HDL-C) level of the subject group as compared... Agent:

20110092564 - Cyclic amino acids for the treatment of pain: Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said composition are for use in the treatment of pain. Pain includes both acute and chronic forms of pain. The preferred cyclic amino acid is 1-aminocyclobutane-1-carboxylic acid (ACBC).... Agent:

20110092578 - Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and mycobacterium species: m

20110092581 - Docetaxel formulations with lipoic acid: Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in... Agent:

20110092580 - Docetaxel formulations with lipoic acid and/or dihydrolipoic acid: Formulations comprising docetaxel or a salt thereof in combination with α-lipoic acid and/or dihydrolipoic acid and/or salts thereof in narrow concentration ranges have improved stability as concentrate liquid formulations and permit longer times between dilution from higher concentrations through completion of infusions prepared therefrom allowing for lesser waste and more... Agent: Scidose LLC

20110092579 - Solubilized formulation of docetaxel: Docetaxel containing formulations having TPGS and being substantially free or totally free of polysorbate surfactants are disclosed wherein stability is enhanced and hypersensitivity reactions are reduced.... Agent: Scidose LLC

20110092582 - New terpenes and macrocycles: Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Type 2, obesity, neuropathy and/or nephropathy.... Agent: Merck Patent Gesellschaft

20110092583 - Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery: Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and/or mixed glycerides and/or free fatty acids containing medium and/or long chain saturated, mono-unsaturated, and/or poly-unsaturated free fatty acids)... Agent: Murty Pharmaceuticals, Inc.

20110092585 - Immunomodulatory pharmaceutical composition and a process for preparation thereof: The present invention provides a novel pharmaceutical composition consisting of a combination of three coumarinolignoids of formula 1, 2 and 3 isolated from the seeds of the plant Cleome viscosa along with a pharmaceutically acceptable carrier useful as a immunomodulator. The invention also describes the ability of the compounds to... Agent: Council Of Scientific And Industrial Research

20110092584 - Therapeutic use of quinonoid derivatives of cannabinoids: The present invention relates to cannabinoic quinone compounds, and especially to their medical use. In particular five cannabinoic quinones, designated HU-331, HU-336, HU-345, HU-395 and HU-396 are herein described as active agents in pharmaceutical compositions. Said compounds and compositions thereof are intended for the treatment of inflammatory, infectious, auto-immune and... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20110092586 - Apoptosis inductor extracted from potato, potato foodstuff containing the inductor, and processed product thereof: An apoptosis inductor is formed of an anthocyanin-containing extract obtained from a potato containing anthocyanine in the skin and flesh thereof. The potato is a potato of cultivated species, such as Solanum tuberosum ssp. andigena L. and S. phureja Juz. et Buk., or of hybrid species based on the cultivated... Agent: National Agricultural Research Organization (naro)

20110092587 - Branched-chain amino acid composition for improving skeletal muscle protein metabolism: The present invention relates to compositions and methods for improving skeletal muscle protein metabolism through encouraging skeletal muscle protein synthesis, reducing skeletal muscle protein degradation, and attenuating inflammatory signaling in exercising muscle.... Agent:

20110092588 - Lactone formulations and method of use: wherein R1-R9 and Y1-Y3 taken independently are preferably a hydrogen atom, a halogen atom, a hydroxyl group, or any other organic groups or groupings which optionally include a heteroatom such as oxygen, sulfur, or nitrogen groupings in linear, branched, or cyclic structural formats; Z and X are independently and preferably... Agent: Magnachem International Laboratories, Inc.

20110092589 - Treatment of inflammatory conditions and diseases with metal-thiols: The present invention provides a method for the treatment of a disease or disorder related to an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a metal and a thiol. In particular, embodiments of the present invention are directed... Agent: The Charlotte-mecklenburg Hospotal Authority

20110092590 - Nitric oxide donating prostamides: Nitroderivatives of prostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Nicox S.a.

20110092591 - Phenyl-prenyl derivatives, of marine and synthetic origin, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders: The present invention is related to a family of phenyl-prenyl derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present... Agent: Noscira S.a.

20110092592 - Diagnosis and treatment of hepatic disorder: Disclosed is a diagnosis or treatment method which utilizes the content of a specific fatty acid in plasma as a marker that reflects the condition of NASH or NAFLD, or utilizes the above-mentioned content in combination with another test, another marker or the like.... Agent:

20110092594 - Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions: The present invention relates to methods of treating lipid disorders, lipid-related disorders or conditions, obesity and obesity-related disorders using nitrated lipids. In particular, the methods comprise administering effective amounts of nitrated fatty acids or esters thereof in order to reduce one or more of triglycerides, free fatty acids, body weight,... Agent:

20110092593 - Water-soluble colonoscopy lubricant: Disclosed is a water-soluble colonoscopy lubricant essentially comprising Polyethylene Glycol 400; Propylene Glycol; and Glycerin. Distilled water may be added as needed to achieve a desired viscosity. Additional ingredients such as a preservative and a pH adjuster may also be added to the colonoscopy lubricant.... Agent:

20110092595 - Compositions and methods for treating lung cancer: Embodiments of the present invention provide compositions and methods for treating lung cancer, including small cell and non-small cell lung cancer that may express HIF-1a by administering a therapeutically effective amount of PX-478.... Agent:

20110092597 - Method for treating herpes virus infection: The present invention is directed to a method for inhibiting herpes viral activity in a subject, by administering to the subject in need thereof an active ingredient consisting essentially of an effective amount of diclofenac (for example, 3-7% w/v) or a pharmaceutically acceptable salt thereof.... Agent:

20110092596 - Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs: Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.... Agent: Johnson Matthey Public Limited Company

20110092598 - Driectly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility,... Agent:

20110092599 - Use of treprostinil to treat neuropathic diabetic foot ulcers: The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising... Agent: United Therapeutics Corporation

20110092600 - Pharmaceutical compositions comprising aminocyclohexane derivatives: The present invention relates to pharmaceutical compositions comprising 1-aminocyclohexane derivatives and a cyclodextrin, which compositions exhibit advantageous safety, convenience, and dosing characteristics. The compositions of the instant invention find particular application in the treatment of various diseases and conditions of the CNS, including those involving the impairment of cognitive function... Agent: Merz Pharma Gmbh & Kgaa

20110092601 - Lysine-specific demethylase inhibitors: Polyamine, polyamine/guanidino, and polyamine/biguanide compounds bearing allene, propargyl, cyclopropyl, and other reactive moieties are disclosed. The compounds are useful as irreversible inhibitors of the enzyme lysine-specific demethylase-1 and for the treatment of cancer.... Agent: The Johns Hopkins University

20110092602 - Rapidly disintegrating oral compositions of tramadol: The present invention relates to a stable taste masked orally disintegrating pharmaceutical composition of tramadol comprising of 3% to 30% w/w of tramadol, 2% to 30% w/w of an ion exchange resin, 0.01 to about 2% w/w of binder and pharmaceutically acceptable excipients to equal 100% w/w, wherein the binder... Agent:

20110092603 - Composition to enhance the bioavailability of curcumin: A composition having a curcuminoid and an essential oil of turmeric. A composition having a curcuminoid and an essential oil of turmeric, wherein the essential oil is present in an amount sufficient to cause an enhancement of bioavailability of curcumin when the composition is administered to a human as compared... Agent:

20110092604 - Fragrance substance mixtures comprising isolongifolanol and musk: c

20110092605 - Encapsulation: Disclosed are encapsulating methods and encapsulated products. A payload material may be encapsulated within a wall material. The carrier material and payload material form a combination that is at least substantially solid at room temperature but that is sufficiently fluid at milling temperature to permit milling and subsequent encapsulation. The... Agent: Appleton Papers Inc.

  
04/14/2011 > patent applications in patent subcategories. category listing, related patent applications

20110086794 - Delivery agent: A composition and method for delivering a peptide or protein into a cell.... Agent: Fermentas Uab

20110086795 - Small peptide modulators of potassium channel trafficking: Provided herein are peptide modulators of ion channels. Specifically, the peptide modulators comprise the amino acid sequence VEDEC wherein V is valine, E is glutamate, D is aspartate, C is cysteine. In certain embodiments, the modulator is attached to the C-terminal end of Slo1 protein isoform. The present invention also... Agent:

20110086796 - Methods for predicting the development and resolution of acute respiratory distress syndrome: The subject invention features methods for predicting whether a subject at risk of developing Acute Respiratory Distress Syndrome (ARDS) will develop ARDS by determining the amount of elafin present in a subject sample, or by determining the ration of elafin:neutrophil elastase in a subject sample. The invention also features methods... Agent: Harvard University

20110086797 - Control of spore germination: Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from... Agent: The Trustees Of Columbia University In The City Of New York

20110086798 - Erythropoietin compositions: Methods and materials are provided for the production of compositions of erythropoietin protein, wherein said compositions comprise a pre-selected N-linked glycosylation pattern as the predominant N-glycoform.... Agent:

20110086799 - Gnrh ii analogs and uses thereof in the immune system: Specially designed GnRH II analogs that are resistant to degradation by peptidases, are disclosed. The GnRH II analogs incorporate D-Arg, D-Leu, D-tBu-Ser, D-Trp, D-Asn or other active D amino acids at position 6 and aza-Gly-amide or other amino acid-amide at position 10. The D-Arg (6)—GnRH II-aza-Gly (10)-amide, D-Asn—GnRH II-aza-Gly (10)-amide,... Agent:

20110086800 - Screening method for predicting susceptibility to breast cancer: A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc)... Agent:

20110086801 - Prevention and reduction of blood loss: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary... Agent: Dyax Corp.

20110086802 - Methods to increase permeability of corneal epithelium and destabilize stromal collagen fibril network: Methods of increasing the permeability of corneal epithelium to facilitate the diffusion of agents into the collagen fibrillar network of the stroma are provided. Used in combination, these methods open the epithelium to facilitate diffusion of stabilization molecules into the stroma and dissociate bridging molecules from stromal collagen fibers, thereby... Agent:

20110086803 - Peptides containing tryptophan: The present invention relates to a process to produce a composition comprising water-soluble peptides and having a Trp/LNAA ratio of more than 0.15, which comprises hydrolyzing lysozyme, preferably hen eggs lysozyme, to prepare a hydrolysate having a DH of between 5 and 45.... Agent:

20110086804 - Treatment of parkinson's disease: Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used... Agent: Cedars-sinai Medical Center

20110086805 - In vitro method for diagnosing skin cancer: The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO:... Agent: Assistance Publique - Hopitaux De Paris

20110086806 - Polypeptides that bind il-23r: Polypeptides that bind to IL-23R including polypeptides having a multimerizing, e.g. trimerizing, domain and a polypeptide sequence that binds IL-23R. The multimerizing domain may be derived from human tetranectin. IL-23R binding polypeptides inhibit activation of IL-23R by native IL-23 and can be used as therapeutics agents for a variety of... Agent: Anaphore, Inc.

20110086807 - Fibromodulin formulation for reducing corneal scarring: A formulation for reducing corneal scarring and related eye conditions, is disclosed. The formulation comprises an effective amount of fibromodulin and can be administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye.... Agent:

20110086808 - Modified therapeutic agents: The invention provides a modified therapeutic agent, said modified agent comprising three or more membrane binding elements with low membrane affinity covalently associated with the agent which elements are capable of interacting independently and with thermodynamic additivity, with components of cellular or artificial membranes exposed to extracellular fluids wherein at... Agent: Adprotech Limited

20110086809 - Enteral administration of arginine-glutamine dipeptide to support retinal, intestinal, or nervous system development: A method for supporting retinal, intestinal, and/or nervous system development in a neonate is provided. The method involves enterally administering arginine-glutamine dipeptide to a neonate.... Agent:

20110086811 - High-concentration rutin-containing drink: It is an object of the present invention to provide a packaged high-concentration rutin-containing drink suppressed the occurrence of the precipitation though it contains rutin in a high concentration. According to the invention, a packaged high-concentration rutin-containing drink includes rutin and quercetin is provided. The concentration of rutin is in... Agent: Ito En, Ltd.

20110086810 - Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.... Agent: Incyte Corporation

20110086902 - Compounds for the modulation of beta-catenin expression: The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating... Agent: Enzon Pharmaceuticals, Inc.

20110086903 - Emergence of a r-type ca2+ channel (cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage: The invention relates to methods and products for treatment of a neurological defect such as a subarachnoid hemorrhage or cerebral vasospasm. Specifically, R-type voltage-gated calcium channel inhibitors and related compositions and kits are described.... Agent:

20110086901 - Oligonucleotides affecting expression of phosphodiesterases: The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as... Agent: Topigen Pharmaceuticals Inc.

20110086904 - Generation of hyperstable mrnas: Provided herein is a method for enhancing the stability of a mRNA molecule. Specifically, the invention provides methods of increasing stability or augmenting expression of mRNA or its products by inserting a stability inducing motif at the 3′UTR of the molecule.... Agent: The Trustees Of The University Of Pennsylvania

20110086906 - Methods for treatment or prevention of diseases associated with functional disorder of regulatory t cells: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by... Agent:

20110086905 - Pseudocomplementary oligonucleotides for targeted gene therapy: Compositions and methods for targeted gene therapy are disclosed. Compositions containing double duplex-forming pseudocomplementary oligonucleotides are administered in combination with a donor oligonucleotide that is homologous to a target sequence on a double-stranded DNA molecule in need of repair or replacement. By activating cellular mechanisms involved in DNA synthesis, repair... Agent: Yale University

20110086812 - Transition state sturcture of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases: Provided are methods of designing a putative inhibitor of a 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. The methods comprise designing a chemically stable compound that resembles the charge and geometry of the 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase transition state. Also provided are methods of inhibiting 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidases using the inhibitors found by the above methods.... Agent:

20110086813 - Compounds for treating bacterial infections: The present invention relates to a novel class of guanine nucleotide analogs which inhibit RelA and Relseq synthetic activity and which possess anti-bacterial activity. The present invention also relates to pharmaceutical compositions that include such compounds, and to methods of use of such compounds or compositions for combating bacteria and... Agent:

20110086814 - Inhibiting e.sakazakii growth: The present invention concerns the use of uronic acid saccharide for preventing growth of Enterobacter sakazakii.... Agent: N.v. Nutricia

20110086815 - Novel compositions containing xanthohumol-cyclodextrin complexes: The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.... Agent: Flaxan Gmbh & Co. Kg

20110086817 - Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria: Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.... Agent: University Of Notre Dame Du Lac

20110086816 - Antimicrobial compounds: The invention relates to cationic siloxane derivatives for use especially as fungicides and/or antiadhesives. The cationic siloxane derivatives have the formula (I), wherein R1, R2, R3, R4, R4′, R5 and n are as defined in the description.... Agent: Ciba Specialty Chemicals Holding Inc.

20110086818 - Methods, compositions, and kits for treating pain and pruritus: The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while minimizing effects on non-pain-sensing neurons or other types of cells.... Agent: The General Hospital Corporation

20110086819 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent:

20110086820 - Analgesic agent comprising cyclic phosphatidic acid derivative: An object of the present invention is to elucidate an analgesic effect as one of new cPA bioactivities and thus to provide a novel analgesic agent. The present invention provides an analgesic agent which comprises a cyclic phosphatidic acid derivative that is one type of phospholipid.... Agent: Ochanomizu University

20110086822 - Substituted tetracycline compounds: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and... Agent:

20110086821 - Tetracycline compounds for treatment of cryptosporidium parvum related disorders: Methods and compositions for treating Cryptosporidium parvum related disorders in a mammal are discussed. Several novel tetracycline compounds useful for treating Cryptosporidium parvum related disorders are also included.... Agent: Trustees Of Tufts College

20110086823 - Disinfectant: The invention relates to a disinfectant which comprises a special combination of biocidal phenols and, where appropriate, phenol derivatives and a keratolytic. The disinfectant is particularly suitable for controlling parasitic protozoa including their persistent forms.... Agent: Lanxess Deutschland Gmbh

20110086824 - (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3: This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3 analogs, and specifically(20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits significant vitamin D receptor binding activity and transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer... Agent: Wisconsin Alumni Research Foundation

20110086825 - Therapeutic vaginal emollient: A topical composition for relief from certain menopausal, peri- and post-menopausal symptoms is disclosed, consisting of a low dosage of progesterone, testosterone and estriol in a pharmaceutically acceptable topical carrier in a weight ratio of from about 1:0.1:0.01 to about 1:0.1:0.02, respectively. In a preferred single dose, the three active... Agent:

20110086826 - Liposomal camptothecins and uses thereof: This invention relates to improved liposomal camptothecin compositions and methods of manufacturing and using such compositions for treating neoplasia and for inhibiting angiogenesis.... Agent: Tekmira Pharmaceuticals Corporation

20110086827 - Combination medicament: The subject matter of this application relates to the combination of ciclesonide or an epimer thereof with R,R-formoterol or a salt, or a hydrate of a salt thereof.... Agent: Nycomed Gmbh

20110086828 - Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors: The present invention provides methods for reducing alcohol drinking behavior in humans and treating acute alcohol poisoning through the use of neutral or negative modulating agents of the neurosteroid sites on GABAA receptors. These agents avoid the unwanted side-effects of opiate antagonists and displays specificity toward the neurosteroid binding sites... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

20110086829 - Compositions and methods for treating obesity: Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some embodiments, pharmaceutical formulations include a combination of two or more biocompatible emulsifiers effective to treat obesity.... Agent:

20110086830 - Metal complexes of n-heterocyclic carbenes: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more... Agent: The University Of Akron

20110086831 - Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack: The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in... Agent: B.r.a.h.m.s Gmbh

20110086833 - Methods for treating spinal muscular atrophy: The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in... Agent:

20110086834 - Alkynyl alcohols as kinase inhibitors: Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.... Agent: Amgen Inc.

20110086837 - Combinations of a pi3k inhibitor and a mek inhibitor: The invention relates methods of treating a patient with locally advanced or metastatic solid tumors with a combination of an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) and an inhibitor of mitogen activated protein kinase (MEK) described herein.... Agent: Genentech, Inc.

20110086839 - Compounds: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent:

20110086838 - Novel compounds as cannabinoid receptor ligands: e

20110086835 - Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.... Agent: Incyte Corporation, A Delaware Corporation

20110086836 - Substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators: The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such... Agent: Santhera Pharmaceuticals (schweiz) Ag

20110086832 - Novel compounds as cannabinoid receptor ligands: e

20110086840 - N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use:

20110086841 - N-9 substituted purine compounds, compositions and methods of use:

20110086842 - Pyrimidines as plk inhibitors:

20110086843 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Merck Serono Sa

20110086844 - Oral solid solution formulation of a poorly water-soluble active substance: e

20110086845 - Compositions and methods for treating neurodegenerating diseases: This invention provides agents, compositions, pharmaceutical compositions and methods for treating or slowing the progression of a neurodegenerating disease, such as Alzheimer's disease and a demyelinating disease.... Agent: The Board Of Trustees Of The University Of Illinois

20110086846 - Azaindazole compounds as ccr1 receptor antagonists: i

20110086847 - Thiadiazole modulators of beta adrenergic receptor: The present invention relates to new thiadiazole modulators of beta adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110086848 - Agrochemical compositions comprising alkyl polypropylene glycol polyethylene glycol: What is described are specific agrochemical compositions comprising alkyl polypropylene glycol polyethylene glycol, processes for their preparation and the use of corresponding compositions in the agrochemical field. The present invention furthermore relates to the use of alkyl polypropylene glycol polyethylene glycol as penetrant for agrochemically active compounds and/or as spontaneity... Agent: Bayer Cropscience Ag

20110086849 - novel benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and ause thereof: a

20110086850 - Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy: Provided herein is a method of radiosensitizing a tumor in a subject, which comprises administering to the subject a radiosensitizing amount of an indazolpyrrolotriazine of Formula I. Also provided herein is a method of treating a tumor in a subject, which comprises the steps of administering to the subject a... Agent: Board Of Regents, The University Of Texas System

20110086851 - Substituted quinazolines and their uses for myeoloprolific and thrombotic diseases: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent:

20110086852 - Pharmaceutical compounds: Compounds of formula (I), wherein R1-R4, X, Y and Z are as defined in claims, exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.... Agent: Orion Corporation

20110086853 - Therapeutic compounds: m

20110086854 - Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions:

20110086855 - Novel compounds as cannabinoid receptor ligands and uses thereof:

20110086856 - Compositions useful as inhibitors of protein kinases: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110086857 - N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes: or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having unexpected dual CCR-2 and CCR-5 receptor activity. Crystalline forms, metabolites, pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases are also disclosed. The... Agent: Bristol-myers Squibb Company

20110086858 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20110086859 - Alkyl substituted indoloquinoxalines: e

20110086860 - Compound: wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc., which may be substituted; R1 and R2 represent, for example, a... Agent:

20110086861 - Pharmaceutical compositions and methods for the treatment of cancer: e

20110086862 - Polymorphs of pardoprunox: The invention also relates to polymorphic forms of said compound, as well as to pharmaceutical compositions containing these compounds, to methods for preparing the compounds, to methods for preparing intermediates useful for their synthesis, and to methods for preparing compositions containing these compounds. The invention also relates to the use... Agent:

20110086863 - Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor: e

20110086864 - N-hydroxyamide derivatives and use thereof: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent:

20110086865 - Ant-ligands molecules and biological applications: e

20110086866 - Inhibitors of bruton's tyrosine kinase: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20110086868 - Specific inhibitors for vascular endothelial growth factor receptors: The present application describes isoindoles and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful inhibitors of VEGFR.... Agent: Nova Southeastern University

20110086867 - 6-(c2-6alkylseleno)purines and methods for treating neural measles viral infection therewith: The present application relates to anti-viral selenopurine compounds of formula (I): wherein R1 is C2-6alkyl, and pharmaceutically acceptable salts, solvates, and prodrugs thereof. These 6-(C2-6alkylseleno)purine compounds find use in the treatment of neural measles virus infection and associated diseases (namely, multiple sclerosis or neural measles). A particularly preferred compound is... Agent:

20110086869 - Methods for treating viral disorders: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of... Agent: The Trustees Of Boston University

20110086870 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Astrazeneca Ab

20110086871 - Rifaximin compositions and method of use: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.... Agent: Alfa Wassermann, S.p.a.

20110086872 - Berberine as a selective lung cancer agent and other compositions and methods: Berberine or its salts or derivatives are identified as the active compound for selectively inhibiting lung cancer, potentially without toxic side effects. Berberine is preferably obtained by synthesis or partial synthesis, or is obtained from natural sources, such as Coptis teeta, or other berberine containing plants. Berberine and its derivatives... Agent:

20110086873 - Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or... Agent:

20110086874 - Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia: A method of converting a treatment for pain comprising intravenous administration of opioids, to a treatment for pain comprising oral administration of a first dose of an immediate release morphine-oxycodone combination in patients in need of analgesia. The method may comprise (1) determining a four-hour average oral morphine equivalents or... Agent:

20110086875 - Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue: Use of ascorbic acid in the manufacture of a powdered medicament for nasal delivery, said medicament comprising an active agent such as apomorphine that exhibits toxicity to ciliated tissue, for ameliorating said toxicity.... Agent: Britannia Pharmaceuticals Limited

20110086876 - Stable sns-595 compositions and methods of preparation: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.... Agent:

20110086877 - Small molecule inhibitors of botulinum neurotoxins: Disclosed herein are methods of inhibiting the activity of Botulinum neurotoxin A metalloprotease with the compounds disclosed herein. Also disclosed are methods of treating, inhibiting or preventing intoxication caused by bacteria of at least one bacterial strain in a subject, and pharmaceutical and cosmetic compositions comprising the compounds disclosed herein.... Agent:

20110086878 - Treatments for neuropathy: Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds,... Agent:

20110086879 - Carboxamide compounds and their use as calpain inhibitors: in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or... Agent: Abbott Laboratories

20110086880 - Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel alkyl substituted piperidine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent:

20110086881 - Crystalline forms of a dimethylphenyl compound: The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example,... Agent: Theravance, Inc.

20110086884 - Barium salt of benzimidazole derivative: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.... Agent:

20110086883 - Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent:

20110086882 - Pyrazolothiazole compound: wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22... Agent: Eisai R&d Management Co., Ltd.

20110086885 - Indole-2-carboxylic acid amides: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.... Agent:

20110086886 - Insecticidal isoxazolines: wherein A represents C or N; R represents haloalkyl; X represents halogen or haloalkyl; l represents 0, 1 or 2; Y represents halogen, alkyl, alkoxy, haloalkyl, cyano, nitro, amino, acylamino, alkoxycarbonylamino, haloalkoxycarbonyl-amino or alkylsulfonylamino; m represents 0, 1 or 2; and G represents any one selected from heterocyclic groups described... Agent: Bayer Cropscience Ag

20110086888 - Fungicidally active compound combinations: e

20110086887 - Oil-based suspension concentrates: The present invention relates to new, oil-based suspension concentrates of active agrochemicals, to a process for producing these formulations and to their use for applying the active substances comprised.... Agent: Bayer Corpscience Ag

20110086889 - Tetrazole compounds as orexin receptor antagonists: The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.... Agent:

20110086890 - Liquid pest control formulation: The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paraesthesia of the... Agent: Redline Products, Inc.

20110086891 - Solid forms of 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide): This invention relates to solid forms of 2-(2,4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide and pharmaceutical compositions thereof, and methods and uses therewith.... Agent: Vertex Pharmaceuticals Incorporated

20110086892 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Ekr Therapeutics, Inc.

20110086893 - Oxa- and thiadiazoles and their use as metalloproteinase inhibitors: Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.... Agent: Laboratoires Serono S.a.

20110086894 - Biomarkers for the diagnosis of als: Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20110086895 - Thiazolidinedione energy restriction-mimetic agents: A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the... Agent: The Ohio State University Research Foundation

20110086896 - Crystalline and stable form of andolast: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary... Agent: Rottapharm S.p.a.

20110086897 - (e)-n-(2-amino-phenyl)-3--acrylamide salts: A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-beπzenesulfonyl]-1H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate.... Agent: 4sc Ag

20110086898 - Pyrazolooxazole compound: wherein R1 and R2 are the same or different and are a hydrogen atom, a C1-6 alkyl group, a cyclic group selected from a C3-6 cycloalkyl group, a tetrahydropyranyl group, a dihydropyranyl group, a tetrahydrofuryl group, a dioxanyl group, a tetrahydrothienyl group, a dithianyl group and a hexahydrothiepinyl group, a... Agent: Eisai R&d Management Co., Ltd.

20110086899 - Pharmaceutical compositions for oral administration: This invention is directed to pharmaceutical compositions for oral administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as a single stereoisomer or as a mixture thereof, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases... Agent: Xenon Pharmaceuticals Inc.

20110086900 - Compositions for prevention/prophylactic treatment of poison ivy dermatitis: The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards... Agent:

20110086907 - Acne treatment: The invention relates to the use of lipooxigenase inhibitors for treating acne, particularly inflammatory acne. The inventive lipooxigenase inhibitor can be used alone or in combination with other lipooxigenase inhibitors or anti-acne active agents in a pharmaceutically suitable composition, particularly through oral and/or local-topic application.... Agent:

20110086908 - Use of phosphatase inhibitors for the treatment of neurodegenerative diseases: Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described.... Agent:

20110086909 - Synthesis of fr901464 and analogs with antitumor activity: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.... Agent: University Of Pittsburgh-- Of The Commonwealth System Of Higher Education

20110086910 - Method of treating or preventing pain: the dotted line represents a single or a double bond; and R5 and R5′ are independently —H, —OH or —OR6, where R6 is a linear or branched C1-C4 alkyl; X is —CH2O—; Z is —CH2CH2O—, —CH(CH3)CH2O— or —CH2CH(CH3)O—; m is 1; and n is an integer of 1-5. The compounds... Agent: Novaremed Limited

20110086911 - Novel bismuth(iii) nsaid compounds and methods for their use: The bismuth(III) tris-carboxylate complexes of the invention may be formulated for use in treatments for a wide range of ailments, particularly those where an anti-microbial activity is advantageous. In a particularly preferred embodiment the bismuth(III) tris-carboxylate complexes of the present invention exhibit activity against bacteria found in the gastrointestinal tract... Agent: Monash University

20110086912 - Derivatives of propane diyl dicinnamate: wherein R1, R2, R3, R4, R5, R6 and R7 are independently H, OH, alkylcarbonyloxy, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (II) or (II)′, wherein R1 and R2 are independently OH, alkoxy or alkylcarbonyloxy, R3 and R4 are independently H, OH, alkoxy or alkylcarbonyloxy,... Agent:

20110086913 - Methods for treating myofascial, muscle, and/or back pain: The present disclosure is drawn to methods for treating myofascial pain, muscle pain, back pain, or combinations of these pains. Specifically, a method for treating myofascial pain, muscle pain, back pain, or combinations thereof includes the application of an analgesic system to a skin surface of a subject experiencing the... Agent:

20110086914 - Methods for treating traumatic brain injury: The present disclosure provides methods of treating traumatic brain injury.... Agent:

20110086915 - Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2—CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms;... Agent:

20110086916 - Interval therapy for the treatment of tinnitus: The present invention relates to interval and/or maintenance therapy employing 1-amino-alkylcyclohexane derivatives (e.g., neramexane or a pharmaceutically acceptable salt thereof) for the treatment of an individual afflicted with tinnitus.... Agent: Merz Pharma Gmbh & Co. Kgaa

20110086917 - Use of l-carnitine for the treatment of cardiovascular diesases: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20110086918 - Broad spectrum preservation blends: A composition having effective broad spectrum preservation activity comprising benzyl alcohol, salicylic acid, sorbic acid and a compound selected from the group consisting of 1,3-propanediol, glycerin and combinations thereof.... Agent:

20110086919 - High eicosapentaenoic acid producing strains of yarrowia lipolytica: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 25% eicosapentaenoic acid (EPA, an ω-3 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases and optionally comprise various native desaturase and acyltransferase knockouts... Agent: E. I. Du Pont De Nemours And Company

20110086920 - Gamma glutamylcysteine treatment or prevention of oxidative injury: The present invention concerns the γ-glutamylcysteine treatment to reduce oxidative damage caused by ischemia/reperfusion events such as pulmonary hypertension, transplant, cardiac bypass and other surgeries, and trauma. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.... Agent:

20110086921 - Novel polymorphic forms of (4--2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid: Polymorphic forms 1 and 2 of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such polymorphs and the use of such polymorphs in medicine.... Agent:

20110086922 - Sensory-specific local anesthesia and prolonged duration local anesthesia: Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block over motor block. The duration of block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is... Agent: Children's Medical Center Corporation

20110086923 - Method to increase oxygen in male and female sexual organs through the topical use of perfluorocarbons: The subject application provides for a method of increasing oxygen level in a sex organ of a subject comprising topically administering to the subject an amount of a perfluorocarbon effective to increase the oxygen level in the sex organ of the subject. The subject application also provides for the use... Agent:

20110086924 - Method of manufacturing an eutectic crystalline sugar alcohol: A method of manufacturing an eutectic crystalline sorbitol/maltitol that represents a single melting peak obtained by differential scanning calorimetry. The method includes combining a liquid composition containing two or more kinds of the sugar alcohol at a predetermined ratio with a powder containing crystals of the same two or more... Agent: B Food Science Co., Ltd.

20110086926 - Disabling thymus gland as a new method for treatment of multiple sclerosis: m

20110086925 - Method and system to detect, diagnose, and monitor the progression of alzheimer's disease: Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of Alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component... Agent:

  
04/07/2011 > patent applications in patent subcategories. category listing, related patent applications

20110082071 - Delivery system for an active ingredient: The invention relates to a delivery system for an active ingredient. The system provides an encapsulating material for the active ingredient, wherein the encapsulating material is formed by combining a cationic component, an anionic component and the active ingredient. The anionic component is a mixture of carbonate and phosphate moieties,... Agent:

20110082070 - Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency: The invention relates to a medicament which comprises a peptide extract of avocado and which can also comprise a composition containing D-mannoheptulose and/or perseitol, such as a water-soluble extract of avocado sugars, and/or a peptide extract of lupine. The inventive medicament is intended for the treatment and/or prevention of illnesses... Agent: Laboratoires Expanscience

20110082072 - Methods of inhibiting cell death or inflammation in a mammal: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods... Agent: University Of Washington

20110082073 - Modified cpn10 and prr signalling: The present invention relates to isolated Cpn10 polypeptides possessing an increased affinity for a PRR ligand compared to Ala Cpn10 polypeptide. In a further embodiment, the present invention also relates to modified chaperonin 10 polypeptides, and to nucleic acids encoding the same and to compositions comprising such polypeptides and uses... Agent: Cbio Limited

20110082074 - Agent for preventing periodontal disease: The present invention provides a pharmaceutical agent that is useful for preventing periodontal disease. The pharmaceutical agent contains a compound in which a mucin-type sugar chain-binding lectin is bound to a polypeptide having an integrin recognition sequence.... Agent: The Doshisha

20110082075 - Anti-viral fusion peptides: Hybrid peptides capable of binding a blood borne virus to a red cell, comprising a viral binding peptide component and a malaria merozoite red cell peptide binding component.... Agent:

20110082076 - Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle... Agent: Novartis Ag

20110082077 - Sialic acid derivatives for protein derivatisation and conjugation: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted... Agent: Lipoxen Technologies Limited

20110082078 - Methods and compositions for treating neuropathies: Disclosed herein are methods and compositions for treating neuropathies by modulating endogenous NT-3 of GDNF gene expression.... Agent: Sangamo Biosciences, Inc.

20110082079 - Glucagon-like peptide-1 derivatives and their pharmaceutical use: The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20,... Agent: Novo Nordisk A/s

20110082080 - Compositions and methods of using the human proislet peptide receptor: Methods and compositions related to the use of Human proIslet Peptide Receptor (HIP) are disclosed herein. Compositions include peptides and peptidomimetics capable of binding the HIP receptors. Methods include screening assays for ligands of receptors and proteins involved in islet cell signaling.... Agent: Curedm Group Holdings, LLC

20110082081 - Compositions and methods for repair of tissues: Biomaterials providing sustained release of growth factor for repair of tissues such as bone and cartilage are disclosed. The biomaterials comprise a proteoglycan derived from domain I of perlecan and a growth factor, and, optionally, collagen.... Agent: University Of Delaware

20110082082 - Skin wound healing compositions and methods of use thereof: A wound healing composition comprising a class of polypeptide compounds having a polypeptide chain with 5 to 120 amino acid units per chain. The composition includes a pharmaceutical medium to carry the polypeptide compound, such as an aqueous solution, suspension, dispersion, salve, ointment, gel, cream, lotion, spray or paste. Additionally,... Agent: University Of Southern California

20110082083 - Formulations of liquid stable antithrombin: In one aspect, the invention provides liquid stable formulations of antithrombin.... Agent: Gtc Biotherapeutics, Inc.

20110082084 - Methods for the prevention or treatment of heart failure: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.... Agent:

20110082085 - Peptides derived from the c2 domain of epsilon pkc and methods of use, thereof: Peptides derived from the C2 regions of εPKC and methods of use, thereof, are described. These peptides modulate the activity of εPKC in an animal model of acute ischemic heart disease.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110082086 - Medicament for use in connection with cartilage impairment: Use of a substance for treating joint medical conditions. The use includes the use of alpha-ketoglutarate acid.... Agent: Entress Ab

20110082087 - Compounds for treating pain: e

20110082089 - Biomarkers for monitoring or predicting the treatment of cancer: Within the context of said biomarkers, the invention concerns a composition for qualifying the c-myc activity in a patient suffering or being susceptible to cancer or for classifying a patient suffering from or being susceptible to lung cancer or bronchial dysplasia, in particular by an in vitro body fluid analysis,... Agent:

20110082088 - Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent: Described herein is a combination therapy suited to the treatment of pancreatic cancer and the like. Also described is a method of potentiating the therapeutic effect of chemotherapeutic agents such as gemcitabine.... Agent: Oncotherapy Science, Inc.

20110082090 - Compounds suited as nanocarriers for active agents and their use: s

20110082091 - Method for preclinical testing of immunomodulatory drugs: The invention teaches a method for testing a prospective or known immunomodulatory drug for T-cell activation, comprising the step of contacting in-vitro a peripheral blood mononuclear cell (PBMC) culture with a predetermined amount of the prospective or known immunomodulatory drug and observing the PBMC culture for T-cell activation using a... Agent: Theramab Gmbh

20110082092 - Interfering rna delivery system and uses thereof: The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.... Agent: Alcon Research, Ltd.

20110082094 - Mammalian cytokine-like polypeptide-10: A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.... Agent:

20110082093 - Methods and compositions for treating trinucleotide repeat disorders: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.... Agent: Sangamo Biosciences, Inc.

20110082095 - Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or... Agent: Agensys, Inc.

20110082096 - Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases: Embodiments of the present invention concern methods, compositions and uses thereof, relating to at least one of vitiligo, or vitiligo-associated autoimmune/autoinflammatory disease (VAAAD). In particular embodiments, genetic variations in the NALP1 gene are of use to detect, diagnose, predict the risk of or treat at least one of vitiligo or... Agent:

20110082097 - Amino acid composition for improving glucose tolerance: Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.... Agent: Abbott Laboratories

20110082098 - Novobiocin analogues and treatment of polycystic kidney disease: Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue... Agent: University Of Kansas

20110082099 - Methods and compositions for the treatment of cystic fibrosis and related illnesses: The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are... Agent:

20110082185 - Cancer-testis gene silencing agents and uses thereof: The invention relates to methods, formulations and kits useful for inhibiting cancer cell viability, invasion, or migration.... Agent: Ludwig Institute For Cancer Research Ltd.

20110082186 - Compositions for inhibiting gene expression and uses thereof: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features... Agent: Idera Pharmaceuticals, Inc.

20110082188 - Gene expression profiling of inflammatory bowel disease: The present invention relates to methods for identifying and/or classifying patients with inflammatory bowel diseases (IBD), particularly patients with Crohn's disease or ulcerative colitis. Gene expression profiling shows broad and fundamental differences in the pathogenic mechanism of UC and CD. The subject method is based on the findings that certain... Agent: Case Western Reserve University

20110082187 - Markers and methods relating to the assessment of alzheimer's disease: Use of clusterin as a biomarker of Alzheimer's disease (AD), particularly methods and compositions for detection of clusterin in a biological sample and assessment of in vivo pathology, disease severity and rate of clinical progression in a subject having or suspected of having AD.... Agent:

20110082191 - Method for treating or preventing radiation damage by in vivo gene therapy: The current embodiment provides a method and gene therapy for treating or preventing radiation damage using a vector carrying a gene for extracellular superoxide dismutase (ECSOD). The gene therapy can be used to treat a patient with an effective amount of the therapy to limit damage resulting from exposure to... Agent: Spectrum Health Innovations, LLC

20110082190 - Nucleic acids encoding anti-il-12 antibody: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.... Agent:

20110082189 - Use of compounds activating sirt-3 for mimicking exercise: The invention relates to modulation of SIRT3 activity levels. The invention has applications for regulating metabolism and mimicking caloric restriction or exercise in a muscle cell.... Agent: President And Fellows Of Harvard College

20110082101 - Combinations comprising epothilones and anti-metabolites: wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R′ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier and/or, optionally, a standard anti-diarrheal,... Agent:

20110082100 - Therapeutic substances that modulate genome methylation: Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used... Agent:

20110082102 - Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation: The present invention relates to the use of an oligosaccharide, in particular a non-digestible oligosaccharide, composition in the prevention or treatment of inflammation, in particular intestinal inflammation.... Agent:

20110082104 - Alkylated semi synthetic glycosaminoglycosan ethers, and methods for making and using thereof: Described herein is the synthesis of alkylated and semi-synthetic glycosaminoglycosan ethers, referred to herein as “SAGEs.” The synthesis of sulfated alkylated SAGEs is also described. The compounds described herein are useful in a number of applications including wound healing, drug delivery, and the treatment of a number of inflammatory diseases... Agent: University Of Utah Research Foundation

20110082103 - Anoectochilus spp. polysaccharide extracts for stimulating growth of advantageous bacteria, stimuating release of granulocyte colony-stimulating factor, modulating t helper cell type i, and/or modulating t helper cell type ii and uses of the same: An Anoectochilus spp. polysaccharide extract for stimulating the growth of advantageous bacteria, stimulating the release of granulocyte colony-stimulating factor (G-CSF), modulating T helper cell type I (Th1 cell), and/or modulating T helper cell type II (Th2 cell) is provided. The extract comprises an effective amount of a type II arabinogalactan... Agent: China Medical University

20110082105 - Compositions comprising superhydrophilic amphiphilic copolymers and methods of use thereof: Provided are compositions comprising a superhydrophilic amphiphilic copolymer and a carrier and composition comprising a superhydrophilic amphiphilic copolymer, a micellar thickener and a carrier.... Agent:

20110082106 - Methods of activating nkt cells: Provided are methods of activating an NKT cell which include a step of contacting the NKT cell with a sufficient amount of isoglobotrihexosylceramide (iGb3) to induce secretion of a cytokine from the NKT cell, stimulate proliferation of the NKT cell or upregulate expression of a cell surface marker on the... Agent: The Scripps Research Institute

20110082107 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a... Agent: Biovitrum Ab

20110082109 - Novel acyl guanidine derivatives: The present invention provides a pharmaceutical which possesses an excellent inhibitory effect on NHE3 (Na+/H+ exchanger type 3) and effectively improves diseases or conditions of organs in which NHE3 is expressed.... Agent: Ajinomoto Co., Inc.

20110082108 - Peptidomimetic inhibitors of post-proline cleaving enzymes: The present invention relates to inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes... Agent: Trustees Of Tufts College

20110082110 - Water-soluble benzoazepine compound and its pharmaceutical composition: wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and... Agent: Otsuka Pharmaceutical Co., Ltd.

20110082111 - Polo-like kinase inhibitors: e

20110082112 - Antiviral phosphinate compounds: The invention is related to a method of treating disorders associated with hepatitis C by administering to an individual a pharmaceutical composition which comprises a therapeutically effective amount of an anti-viral phosphinate compound.... Agent: Gilead Sciences, Inc.

20110082113 - Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity: e

20110082114 - Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors: The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-10. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present... Agent: Symphony Evolution, Inc.

20110082115 - Methods for providing a system of care for an oxazaphosphorine drug regimen: The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration.... Agent: Accentia Biopharmaceuticals, Inc.

20110082116 - Novel compounds as cannabinoid receptor ligands: e

20110082117 - Phenyl sulfonamides as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110082118 - Onychomycosis treatment delivery system: A topical treatment for onychomycosis and Tinea pedis comprising a delivery system further comprising at least one hydroxy acid agent having a pH-pKa value of 0.5 or greater and at least one antifungal agent formulated into creams, lotions, gels, sprays, foams, pads, films, patches, and solutions.... Agent:

20110082119 - Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis: A prophylactic/ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ω3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a... Agent:

20110082120 - Substituted thioacetic acid salicylate derivatives and their uses: The invention relates to substituted thioacetic acid salicylate derivatives; compositions comprising an effective amount of a substituted thioacetic acid salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a substituted thioacetic acid salicylate derivative.... Agent:

20110082121 - 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses: This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or... Agent: Wisconsin Alumni Research Foundation

20110082122 - 19-nor-vitamin d analogs with 1,2- or 3,2-cyclopentene ring: 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some... Agent: Wisconsin Alumni Research Foundation

20110082123 - 6-methylvitamin d3 analogs and their uses: This invention discloses 6-methylvitamin D3 analogs, and specifically 1α,25-dihydroxy-6-methylvitamin D3, and pharmaceutical uses therefor. This compound exhibits vitamin D receptor binding activity and transcription activity as well as activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent,... Agent: Wisconsin Alumni Research Foundation

20110082124 - Detergent compositions for treatment of lipomas and other conditions: A method of treating a lipoma involves contacting the lipoma with a detergent to dissolve the lipoma. For example, the detergent may be a cholate, deoxycholate or similar detergent. A method of treating cellulite and extra fat deposits involves contacting them with a detergent to help the dissolving of the... Agent: Kythera Biopharmaceuticals, Inc.

20110082126 - Method for treating inflammatory conditions: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.... Agent:

20110082125 - Topical ophthalmic or otic solution formulations containing moxifloxacin hydrocholoride and dexamethasone phosphate: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.... Agent: Alcon Research, Ltd

20110082127 - New injectable formulations containing progesterone: The present invention relates to injectable progesterone formulations and processes for their preparation.... Agent:

20110082128 - In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts: An in-situ gel ophthalmic drug delivery system for estrogen containing an estrogen, a solubilizing and complexing agent, a humectant, a sorbic acid or sorbic acid based stabilizer, an optional chelating agent and gellan gum in the amount of about 0.1-0.5% w/v, optionally 0.1-0.3% w/v, of the composition.... Agent:

20110082129 - Organic compounds: The present invention provides novel organic compounds of Formula I: methods of use, and pharmaceutical compositions thereof.... Agent:

20110082130 - Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals... Agent: Ligand Pharmaceuticals, Inc.

20110082131 - Triazole derivatives useful as axl inhibitors: Methods of using triazole derivatives in treating diseases or conditions associated with Axl catalytic activity are disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110082133 - Pyridone compounds: [Means for Solution] The present inventors have conducted extensive studies on EP4 receptor agonists, and as a result, have found that a novel pyridone compound, in which a group having an acidic group is substituted at the 1-position of the pyridone ring, the 6-position is bonded with an aromatic ring... Agent:

20110082132 - [4-(1-amino-ehtyl) - cyclohexyl] -methyl-amine and [6-(1-amino-ehtyl) -tetrahydro-pyran-3-yl] -methyl-amine derivatives as antibacterials: e

20110082134 - 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia:

20110082135 - Inhibitors of akt activity: The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound... Agent:

20110082136 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a... Agent:

20110082138 - Imidazopyridin-2-one derivatives: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.... Agent: Daiichi Sankyo Company, Limited

20110082137 - New compounds for the treatment of cns disorders: According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use... Agent: Boehringer Ingelheim International Gmbh

20110082139 - Substituted 8-[6-amino-3-pyridyl]xanthines: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.... Agent:

20110082141 - 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is... Agent: Aziende Chim. Riun.ang.franc. A.c.r.a.f. S.p.a.

20110082140 - 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids.: Compounds of the formula (I), in which R1, R2, R3 and R4 have the meanings indicated in claim (1), are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gmbh

20110082143 - Bicyclic heteroaryl compounds: Bicyclic heteroaryl compounds of formula (I) shown below are disclosed. Each variable in formula (I) is defined in the specification. Also disclosed is treatment of cancer with these compounds.... Agent: National Taiwan University

20110082142 - Selective kinase inhibitors: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4... Agent:

20110082144 - N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes: c

20110082145 - Olopatadine compositions and uses thereof:

20110082146 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Rigel Pharmaceuticals, Inc.

20110082147 - Substituted imidazotriazines: This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing partial-agonist activity at the GABA... Agent: Concert Pharmaceuticals, Inc.

20110082148 - Treating, preventing or ameliorating a hyperproliferative disease/disorder: i

20110082149 - Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation: The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.... Agent: Chelsea Therapeutics, Inc.

20110082150 - Headache pre-emption by dihydroergotamine treatment during headache precursor events: Disclosed are methods that address providing a subject experiencing, or who has experienced, a headache precursor event and administering dihydroergotamine, or a pharmaceutically acceptable salt or complex thereof, to the subject by oral inhalation, in an amount effective to pre-empt a subsequent headache in the subject. Also disclosed are compositions... Agent:

20110082151 - Sulfonylurea modulators of endothelin receptor: The present invention relates to new sulfonylurea modulators of endothelin receptor activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110082152 - Therapeutic agents useful for treating pain: wherein Ar, Ar1, Ar2, R3, R4, R5, R6, R13, m, t, and x are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Hydroxyiminopiperazine Compound”); compositions comprising an effective amount of a Hydroxyiminopiperazine Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to... Agent: Purdue Pharma L.p.

20110082153 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).... Agent: Schering Corporation

20110082154 - Sigma ligands for neuronal regeneration and functional recovery: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferably SA-4503, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which... Agent:

20110082155 - Novel 2-pyridone compounds: e

20110082156 - Fatty acid acipimox derivatives and their uses: The invention relates to fatty acid acipimox derivatives; compositions comprising an effective amount of a fatty acid acipimox derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid acipimox derivative.... Agent:

20110082157 - Piperidinylamino-thieno [2,3-d] pyrimidine compounds: The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the... Agent:

20110082158 - Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same: These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting GARFTase and/or other folate metabolizing enzymes in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such... Agent:

20110082159 - Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Incyte Corporation

20110082160 - Synergistic fungicidal mixtures for fungal control in cereals: A fungicidal composition containing a fungicidally effective amount of a compound of Formula I-V and at least one fungicide selected from the group consisting of epoxiconazole, prothioconazole, azoxystrobin, pyraclostrobin, penthiopyrad, isopyrazam, bixafen, boscalid, prochloraz, and chlorothalonil provides synergistic control of selected fungi.... Agent: Dow Agrosciences LLC

20110082161 - Powders for reconstitution: This invention relates to drinkable formulations prepared from powders for reconstitution comprising etravirine (TMC125) dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection.... Agent:

20110082163 - Novel uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity: wherein n represents an integer of 1 to 3; X represents a bond, an oxygen atom, a sulfur atom, or the like; Y represents a linear or branched alkylene group having 1 to 8 carbon atoms, or the like; and Z represents —SO2NR1R2 or —NR3SO2—R4, wherein R1 and R2 each... Agent: Taiho Pharmaceutical Co., Ltd.

20110082162 - Synergistic fungicidal composition containing 5-fluorocytosine for fungal control in cereals: A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of epoxiconazole, prothioconazole, azoxystrobin, pyraclostrobin, penthiopyrad, isopyrazam, bixafen, boscalid, chlorothalonil and isobutyric acid (3S,6S,7R,8R)-8-benzyl-3-[(3-isobutyryloxymethoxy-4-methoxypyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-[1,5]dioxonan-7-yl ester provides synergistic control of selected fungi.... Agent: Dow Agrosciences LLC

20110082164 - Polycyclic compounds as lysophosphatidic acid receptor antagonists: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20110082165 - Pyrrolidine gpr40 modulators: s

20110082166 - Novel 4-benzhydryl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 4-benzhydryl-tetrahydro-pyridine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein Ra represents hydrogen or C1-6-alkyl; Rband Rc independent of each other represent a phenyl group, which phenyl group is... Agent: Neurosearch A/s

20110082167 - Topical compositions of opioid antagonists and methods for treating skin conditions therewith: Provided are topical compositions comprising opioid antagonists, such as naltrexone or naloxone, or their pharmaceutically acceptable salts, and methods for treating skin conditions, such as those caused by human papillomavirus, therewith.... Agent: Mustafa Nevzat Ilac Sanayii A.s.

20110082168 - Compositions for delivering highly water soluble drugs: The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.... Agent: Adventrx Pharmaceuticals, Inc.

20110082169 - Stable sns-595 compositions and methods of preparation: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.... Agent:

20110082170 - Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof: t

20110082171 - Medicaments and methods for inhibition of scarring: Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing of a wound, in which a therapeutically effective amount... Agent: Renovo Limited

20110082173 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of formula: (I) wherein R1, R2, R3, R4 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astrazeneca Ab

20110082172 - Pyrrolidinone carboxamide derivatives: Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor.... Agent: Chemocentryx, Inc.

20110082174 - Solid state forms of racemic ilaprazole: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention... Agent: Il Yang Pharmaceutical Company, Ltd.

20110082175 - Insecticidal aryl pyrrolidines: The present invention provides novel aryl pyrrolidines having an excellent insecticidal action as insecticides. Aryl pyrrolidines represented by the formula (I) and use thereof as insecticide.... Agent: Bayer Cropscience Ag

20110082176 - Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.... Agent: Resverlogix Corp.

20110082177 - N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases: The invention relates to the novel N′-nitroxyalkylnicotinamide derivatives represented by the general formula I wherein R1 is C1-C4 alkyl; R2 is hydrogen. C1-C4 alkyl, CH2OH or CH2ONO2; R3 is ONO2, CH2ONO2 or OH; provided that when R3 is OH, R2 is CH2ONO2; and X− is an organic or inorganic anion;... Agent:

20110082178 - Methods of treating autoimmune and inflammatory diseases and disorders: Heterocyclic compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20110082179 - Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.... Agent:

20110082180 - Antimicrobial compounds: The compounds disclosed herein are isoxazole derivatives that are useful as antimicrobial compounds, particularly as anti-bacterial compounds. The disclosed methods comprise incubating at least two different substrates in the presence of at least one oxygenase to provide the disclosed compounds, or to prepare and identify compounds that have antimicrobial activity.... Agent:

20110082181 - Compounds as lysophosphatidic acid receptor antagonists: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Phamaceuticals, Inc.

20110082182 - Therapeutic antiviral peptides: s

20110082183 - Phenyl pyrrole aminoguanidine derivatives: The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of... Agent: Action Pharma A/s

20110082184 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents: e

20110082192 - Lipoic acid acylated salicylate derivatives and their uses: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.... Agent:

20110082193 - Taxane derivative containing pharmaceutical composition with improved therapeutic efficacy: The invention relates to a pharmaceutical combination comprising a mixture of (a) at least one taxane derivative and (b) at least one ω-3 poly-unsaturated acid or a derivative thereof wherein the molar ratio of (b) to (a) is not higher than 2. The invention further relates to a liquid pharmaceutical... Agent:

20110082194 - Synergistic anticoagulant composition: e

20110082195 - New use for cannabinoids: The present invention relates to the use of CBD alone or in combination with another cannabinoid, in the manufacture of a pharmaceutical or neutraceutical formulation for use in controlling cholesterol levels in a subject. It also relates to the use of THCV alone or in combination with another cannabinoid, in... Agent: Gw Pharma Limited

20110082197 - Method for inhibiting formation and/or activation of osteoclasts using flemingia macrophylla extract or lespedeza flavanone a: e

20110082198 - Theaflavin compositions, production, and methods to control physiological disorders in mammals: A process for producing a purified extract comprising between about 40% and about 90% theaflavins is provided. Purified theaflavin extract produced by the disclosed process is provided which comprises less than about 5% TF1, between about 10% and about 60% TF2a, between about 5% and about 35% TF2b, and between... Agent: Jiangsu Dehe Bio-tech Co., Ltd.

20110082196 - Theaflavin compositions, related processes and methods of use: A process for producing purified theaflavin extract is provided which comprises combining an organic solvent with tea leaves, extracting polyphenols from the tea leaves to produce an organic stock substrate solution; producing a second batch of tea leaves; grinding the second batch of tea leaves to produce stock fermentation enzyme;... Agent: Jiangsu Dehe Bio-tech Co., Ltd.

20110082199 - Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues: A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. The crosslinking reagent includes a crosslinking agent such as genipin and/or... Agent:

20110082200 - 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.... Agent: Alcon, Inc.

20110082201 - Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct: The present invention discloses the use of L-butylphthalide of formula (I) in the manufacture of medicaments for the prevention and treatment of cerebral infarct, especially induced by focal cerebral ischemia.... Agent:

20110082202 - Fatty acid acifran derivatives and their uses: The invention relates to fatty acid acifran derivatives; compositions comprising an effective amount of a fatty acid acifran derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid acifran derivative.... Agent:

20110082204 - N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid ester as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of increasing alertness, and decreasing fatigue or sleepiness,... Agent:

20110082203 - Process to diagnose or treat brain injury: A process for diagnosing and treating a neurological condition in a subject is provided that includes assaying a biological sample of a subject for the presence of one or more biomarkers; diagnosing a neurological condition based on a ratio of one or more of the biomarkers in the sample; and... Agent:

20110082205 - Docosahexaenoic acid gel caps: The present invention is directed to an oral dosage form comprising a gel capsule comprising, (a) plasticizer; (b) gelatin; (c) water; and (d) greater than 850 mg DHA ethyl ester, wherein less than about 2% (wt/wt) of the total fatty acid content of the dosage form is EPA, wherein the... Agent:

20110082206 - Heteroatom containing substituted fatty acids: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.... Agent:

20110082207 - Inhibitors of yeast filamentous growth and method of their manufacture: The invention broadly relates to the use of α,β-unsaturated fatty acids to inhibit the filamentous growth of fungi and yeasts and to a method for producing same. In particular the invention relates to the use of optionally substituted C8 to CI5 α,β-unsaturated fatty acids or salts, esters or amides thereof... Agent:

20110082208 - Therapies for cancer using isotopically substituted lysine: Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally.... Agent:

20110082209 - Novel salts of (4--2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid: A series of novel salt forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent:

20110082210 - Fatty acid fibrate derivatives and their uses: The invention relates to fatty acid fibrate derivatives; compositions comprising an effective amount of a fatty acid fibrate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid fibrate derivative.... Agent:

20110082211 - Method for treating tinnitus aureum: A method is described for treating tinnitus aureum in a subject by administering to the subject a therapeutically effective amount of a compound as defined in Formula I herein, illustratively (R)-2-acetamido-N-benzyl-3-methoxypropionamide, or a pharmaceutically acceptable salt thereof.... Agent: Ucb Pharma Gmbh

20110082212 - Multi-substituted selective androgen receptor modulators and methods of use thereof: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.... Agent:

20110082213 - Novel salts of o-desmethyl-venlafaxine: Novel pharmaceutically acceptable salts of desvenlafaxine with physiologically ubiquitous ions selected from sugar acids and vitamins, processes for their preparation, pharmaceutical compositions containing them and uses therefor are described.... Agent:

20110082214 - Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet: Process for preparing a powder comprising the steps of providing at least one first component in liquid form at ambient temperature, providing at least one second component having a melting point or melting range in the range from above ambient temperature to below the degradation temperature of said first component,... Agent: Gruenthal Gmbh

20110082215 - Anthroquinone containing derivatives as biochemical agricultural products: Formulations containing anthraquinone derivatives with increased effectiveness as pesticides are provided. These formulations may comprise (a) a preparation comprising one or more anthraquinone derivatives having activity against plant pests; (b) one or more C2-C7 alcohols, or glycols or lactones; and (c) one or more surfactants selected from the group consisting... Agent: Marrone Bio Innovations

20110082216 - Benzoyl peroxide composition for treating skin: This invention relates to a novel composition useful for the treatment of skin, and more particularly, to a composition containing benzoyl peroxide for treating acne while providing enhanced delivery and low level of irritation to skin.... Agent:

20110082217 - High-clarity aqueous concentrates of 4-hexylresorcinol: The present invention relates to hexylresorcinol/water concentrates that are high in clarity, easily handled, and readily blended with other ingredients to form skin care compositions.... Agent:

20110082218 - Treatment and modulation of gene expression and skin aging: Methods and compositions for treating modulating and/or ameliorating non-light-induced, particularly non-UV-induced, skin aging in a human, for reducing the basal MMP-10 expression in unirradiated cells of an organism and/or reducing the basal MMP-1 RNA transcription and protein translation in unirradiated cells of an organism, and/or for_modulating the effects of UVA-induced... Agent:

20110082219 - Thickeners: t

20110082220 - Porcine umami taste receptors and uses therefor: The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste.... Agent: Lucta

20110082221 - In situ gelling systems as sustained delivery for front of eye: An ophthalmic formulation particularly well suited for use as a delivery vehicle in the sustained delivery of ophthalmic active agents to the eye. The formulations comprise an alginate, wherein the guluronic acid content is in a range of about 35 percent to about 45 percent, and an excipient, preferably gellan... Agent:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141204: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.79557 seconds

PATENT INFO